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Population Stratification is from the 
migration patterns of  haplotypes  
throughout human history 

By Kelly Servick
L
ast month, researchers at Boston 
Children’s Hospital published a study 
that closely examined the DNA of 
158 people with brain malformations 
who had been unable to identify the 
cause of their disorders through clini-
cal genetic testing. With highly sensitive 
sequencing, the group found eight disease-
causing mutations that occurred in only a 
small fraction of each person’s cells, mak-
ing them too subtle for conventional ge-
netic diagnostic tests.
Such genetic variation among cells, 
known as mosaicism, is present in all of us 
and has long been common knowledge. The 
phenomenon was a feature of “college dorm 
room conversations in the decades past,” 
says Chad Shaw, a statistician at Baylor Col-
lege of Medicine in Houston, Texas. “It was 
like, ‘Hey, this will blow your mind.’ ” 
But now that genetic technologies make 
it possible to hunt down specific mutations 
in small numbers of cells, researchers, cli-
nicians, genetic counselors, and funders 
are paying closer attention to mosaicism. 
Next month, the U.S. National Institutes of 
Health (NIH) will begin reviewing applica-
tions for grants to find genetic variation 
in brain tissue that may help explain neu-
ropsychiatric disorders. And as research-
ers find more cases of mosaicism, they’re 
wondering how many genetic causes of 
disease remain invisible to even the best 
clinical tests.
Traditionally, genetic disease research 
has focused on mutations inherited through 
the germ line—the legacy of parents who 
are carriers, or of genetic mistakes dur-
ing the formation of their eggs and sperm. 
These DNA mishaps end up in every cell of 
a child. But once an embryo starts devel-
oping, genetic errors can arise every time 
a cell divides. And because cells can then 
proliferate and spread their mutations, 
each body is “a kind of micro evolutionary 
experiment,” says Leslie Biesecker, a ge-
neticist at NIH’s National Human Genome 
Research Institute in Bethesda, Maryland. 
The number of cells with a given mutation 
depends on when and where the mutation 
arose and how it changes a cell’s function. 
Many such mutations are benign, but some 
cause disease. 
The systematic hunt for disease-causing 
mosaic mutations is only beginning. Some 
are obvious—cases where “nature is stick-
ing its finger in our eye,” Biesecker says. 
In conditions such as McCune-Albright 
syndrome, the abnormal cells can be seen 
as patches or patterns on a person’s skin. 
But any genetic disease could be mosaic. 
Cancers, which consist of genetically dis-
tinct cells, are a familiar example, and are 
a common focus of sequencing efforts. But 
other studies have shown that mosaic mu-
tations can underlie dozens of conditions, 
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other countries to push for access.
Meanwhile, camera networks continu-
ously monitor the night skies with fisheye 
lenses. Some, such as the European Fireball 
Network, are well established, but many rely 
on enthusiastic amateurs and outdated film 
cameras. Philip Bland, a researcher at Curtin 
University, Bentley, in Australia, has larger 
ambitions. By the end of this month, he and 
his colleagues will have finished installing 
some 30 camera stations in the Australian 
outback, covering an area the size of Alaska. 
Each AU$7000 station in the Desert Fire-
ball Network includes a high-resolution 
camera that takes 30-second time-lapse stills 
for calculating trajectories and brightnesses. 
It also has a video camera to determine the 
exact duration of the fireball, which can be 
translated into its speed. The solar-powered 
stations can collect data, unattended, for 
months on end. 
Bland expects to catch between five and 
10 fireballs a year. He also believes that re-
covering the meteorites will be easier than 
it is in places such as Europe—even though 
he often won’t be able to enlist radar to re-
fine his trajectories. This part of Australia 
largely lacks people and precipitation, and 
hence has few weather radars. But the dark 
meteorites should be easy to spot against the 
light-colored, largely barren desert. A camera-
equipped drone will aid the search. 
With such a wide net for trapping space 
rocks, Bland believes that he can start to 
determine the rate at which material from 
space hits the Earth—and not just extra-
terrestrial material. Humanmade space junk 
regularly falls to Earth and can be distin-
guished by its slower speed: Anything that 
strikes the atmosphere at less than 11 kilo-
meters per second can be assumed to have 
been lofted by humans.
All this technology could eventually make 
retrieving meteorite fragments routine and 
efficient. The old way—rare, momentous 
fireball sightings followed by frenzied yet 
agonizingly slow searches on foot—would be 
history. But for now, researchers still thrill to 
the chase. During the radar technique work-
shop, Josep Trigo-Rodríguez, a researcher 
at the Institute of Space Sciences in Barce-
lona, Spain, learned that a massive fireball, 
brighter than the full moon, had been seen 
over Catalonia early on 7 September. Trigo-
Rodríguez worked through the week to re-
fine the meteorite’s trajectory, based on data 
from five fireball network cameras and two 
pictures from eyewitnesses. 
He would not reveal its exact location; he 
sent out a search party last week and did not 
want to be scooped by local meteorite hunt-
ers. But he suspects that several kilograms 
of fresh meteorite are waiting for him some-
where in the northeast of Spain. ■
Harmful mutations can
fly under the radar
With more sensitive genetic tests, researchers are hunting 
the roots of disease in the human “mosaic”
CLINICAL TESTING
Zygote Genetic change Proliferation
Building a human mosaic
Depending on when and where in embryonic development a mutation 
occurs, a subset of adult cells will harbor the genetic change.
Mosaic mutation
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By Kelly Servick
L
ast month, researchers at Boston 
Children’s Hospital published a study 
that closely examined the DNA of 
158 people with brain malformations 
who had been unable to identify the 
cause of their disorders through clini-
cal genetic testing. With highly sensitive 
sequencing, the group found eight disease-
causing mutations that occurred in only a 
small fraction of each person’s cells, mak-
ing them too subtle for conventional ge-
netic diagnostic tests.
Such genetic variation among cells, 
known as mosaicism, is present in all of us 
and has long been common knowledge. The 
phenomenon was a feature of “college dorm 
room conversations in the decades past,” 
says Chad Shaw, a statistician at Baylor Col-
lege of Medicine in Houston, Texas. “It was 
like, ‘Hey, this will blow your mind.’ ” 
But now that genetic technologies make 
it possible to hunt down specific mutations 
in small numbers of cells, researchers, cli-
nicians, genetic counselors, and funders 
are paying closer attention to mosaicism. 
Next month, the U.S. National Institutes of 
Health (NIH) will begin reviewing applica-
tions for grants to find genetic variation 
in brain tissue that may help explain neu-
ropsychiatric disorders. And as research-
ers find more cases of mosaicism, they’re 
wondering how many ge e ic causes of 
disease remain invisible to even the best 
clinical tests.
Traditionally, genetic disease research 
has focused on mutations inherited through 
the germ line—the legacy of parents who 
are carriers, or of genetic mistakes dur-
ing the formation of their eggs and sperm. 
These DNA mishaps end up in every cell of 
a child. But once an embryo starts devel-
oping, genetic errors can arise every time 
a cell divides. And because cells can then 
proliferate and spread their mutations, 
each body is “a kind of micro evolutionary 
experiment,” says Leslie Biesecker, a ge-
neticist at NIH’s National Human Genome 
Research Institute in Bethesda, Maryland. 
The number of cells with a given mutation 
depends on when and where the mutation 
arose and how it changes a cell’s function. 
Many such mutations are benign, but some 
cause disease. 
The systematic hunt for disease-causing 
mosaic mutations is only beginning. Some 
are obvious—cases where “nature is stick-
ing its finger in our eye,” Biesecker says. 
In conditions such as McCune-Albright 
syndrome, the abnormal cells can be seen 
as patches or patterns on a person’s skin. 
But any genetic disease could be mosaic. 
Cancers, which consist of genetically dis-
tinct cells, are a familiar example, and are 
a common focus of sequencing efforts. But 
other studies have shown that mosaic mu-
tations can underlie dozens of conditions, 
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other countries to push for access.
Meanwhile, camera networks continu-
ously monitor the night skies with fisheye 
lenses. Some, such as the European Fireball 
Network, are well established, but many rely 
on enthusiastic amateurs and outdated film 
cameras. Philip Bland, a researcher at Curtin 
University, Bentley, in Australia, has larger 
ambitions. By the end of this month, he and 
his colleagues will have finished installing 
some 30 camera stations in the Australian 
outback, covering an area the size of Alaska. 
Each AU$7000 station in the Desert Fire-
ball Network includes a high-resolution 
camera that takes 30-second time-lapse stills 
for calculating trajectories and brightnesses. 
It also has a video camera to determine the 
exact duration of the fireball, which can be 
translated into its speed. The solar-powered 
stations can collect data, unattended, for 
months on end. 
Bland expects to catch between five and 
10 fireballs a year. He also believes that re-
covering the meteorites will be easier than 
it is in places such as Europe—even though 
he often won’t be able to enlist radar to re-
fine his trajectories. This part of Australia 
largely lacks people and precipitation, and 
hence has few weather radars. But the dark 
meteorites should be easy to spot against the 
light-colored, largely barren desert. A camera-
equipped drone will aid the search. 
With such a wide net for trapping space 
rocks, Bland believes that he can start to 
determine the rate at which material from 
space hits the Earth—and not just extra-
terrestrial material. Humanmade space junk 
regularly falls to Earth and can be distin-
guished by its slower speed: Anything that 
strikes the atmosphere at less than 11 kilo-
meters per second can be assumed to have 
been lofted by humans.
All this technology could eventually make 
retrieving meteorite fragments routine and 
efficient. The old way—rare, momentous 
fireball sightings followed by frenzied yet 
agonizingly slow searches on foot—would be 
history. But for now, researchers still thrill to 
the chase. During the radar technique work-
shop, Josep Trigo-Rodríguez, a researcher 
at the Institute of Space Sciences in Barce-
lona, Spain, learned that a massive fireball, 
brighter than the full moon, had been seen 
over Catalonia early on 7 September. Trigo-
Rodríguez worked through the week to re-
fine the meteorite’s trajectory, based on data 
from five fireball network cameras and two 
pictures from eyewitnesses. 
He would not reveal its exact location; he 
sent out a search party last week and did not 
want to be scooped by local meteorite hunt-
ers. But he suspects that several kilograms 
of fresh meteorite are waiting for him some-
where in the northeast of Spain. ■
Harmful mutations can
fly under the radar
With more sensitive genetic tests, researchers are hunting 
the roots of disease in the human “mosaic”
CLINICAL TESTING
Zygote Genetic change Proliferation
Building a human mosaic
Depending on when and where in embryonic development a mutation 
occurs, a subset of adult cells will harbor the genetic change.
Mosaic mutation
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Beyond	  our	  Kuhnian	  inheritance	  
A	  recent	  lecture	  by	  Prof	  Greg	  Radick	  ques)ons	  our	  scien)ﬁc	  inheritance,	  
through	  textbook	  histories	  of	  gene)cs	  and	  Thomas	  Kuhn's	  legacy	  
hXp://www.guardian.co.uk/science/the-­‐h-­‐word/2012/aug/28/thomas-­‐
kuhn	  
Walter	  Frank	  Raphael	  Weldon	  
Vs.	  	  
William	  Bateson	  
Forthcoming	  by	  Greg	  Radick.	  Scholarly	  edi)on	  of	  W.	  F.	  R.	  Weldon's	  Theory	  of	  
Inheritance	  (1904-­‐1905),	  coedited	  with	  Annie	  Jamieson.	  
Mendel’s laws of alternative inheritance in peas 29 
ESP FO U N D A T IO N S  SE R IE S  
PLATES. 
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MENDEL’S LAWS  
OF  
ALTERNATIVE INHERITANCE IN PEAS. 
W. F.  R.  WELD O N 
 
 
 
 
 
 
 
 
 
Weldon, W. F. R. 1902. Mendel’s laws of alternative 
inheritance in peas. Biometrika, 1:228-254. 
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•  “The	  fundamental	  mistake	  which	  vi4ates	  all	  work	  
based	  upon	  Mendel’s	  method	  is	  the	  neglect	  of	  ancestry,	  
and	  the	  a>empt	  to	  regard	  the	  whole	  eﬀect	  upon	  
oﬀspring,	  produced	  by	  a	  par4cular	  parent,	  as	  due	  to	  
the	  existence	  in	  the	  parent	  of	  par4cular	  structural	  
characters;	  while	  the	  contradictory	  results	  obtained	  by	  
those	  who	  have	  observed	  the	  oﬀspring	  of	  parents	  
apparently	  iden4cal	  in	  certain	  characters	  show	  clearly	  
enough	  that	  not	  only	  the	  parents	  themselves,	  but	  their	  
race,	  that	  is	  their	  ancestry,	  must	  be	  taken	  into	  account	  
before	  the	  result	  of	  pairing	  them	  can	  be	  predicted”	  –	  
Walter	  Frank	  Raphael	  Weldon	  (Weldon,	  1902).	  
	  

“Biological	  Indeterminacy”	  
•  Bateson	  became	  famous	  as	  the	  outspoken	  
Mendelian	  antagonist	  of	  Walter	  Raphael	  Weldon,	  
his	  former	  teacher,	  and	  Karl	  Pearson	  who	  led	  the	  
biometric	  school	  of	  thinking.	  This	  concerned	  the	  
debate	  over	  salta)onism	  versus	  gradualism	  
(Darwin	  had	  been	  a	  gradualist,	  but	  Bateson	  was	  a	  
salta)onist).	  Later,	  Ronald	  Fisher	  and	  
J.B.S.	  Haldane	  showed	  that	  discrete	  muta)ons	  
were	  compa)ble	  with	  gradual	  evolu)on:	  see	  the	  
modern	  evolu)onary	  synthesis.	  
Biological	  Indeterminacy.	  Greenspan	  RJ.	  Sci	  Eng	  
Ethics.	  2012	  Jul	  3	  
	  
Biological	  Robustness.	  
The	  canalisa)on	  metaphor	  suggests	  that	  phenotypes	  are	  very	  robust	  to	  small	  perturba)ons,	  
for	  which	  development	  does	  not	  exit	  the	  canal,	  and	  rapidly	  returns	  back	  down,	  with	  liXle	  
eﬀect	  on	  the	  ﬁnal	  outcome	  of	  development.	  But	  perturba)ons	  whose	  magnitude	  exceeds	  a	  
certain	  threshold	  will	  break	  out	  of	  the	  canal,	  moving	  the	  developmental	  process	  into	  
uncharted	  territory.	  Strong	  robustness	  up	  to	  a	  limit,	  with	  liXle	  robustness	  beyond,	  is	  a	  paXern	  
that	  could	  increase	  evolvability	  in	  a	  ﬂuctua)ng	  environment.	  
E.	  coli	  adap)ng	  to	  low	  glucose	  condi)ons,	  in	  the	  context	  of	  media	  containing	  citrate.	  
–	  Richard	  Lemski	  experiment	  	  
"Finally,	  novel	  func)ons	  ohen	  emerge	  in	  rudimentary	  forms	  that	  must	  be	  reﬁned	  to	  
exploit	  the	  ecological	  opportuni)es.	  This	  three-­‐step	  process	  —	  in	  which	  poten)a)on	  
makes	  a	  trait	  possible,	  actualiza)on	  makes	  the	  trait	  manifest,	  and	  reﬁnement	  makes	  
it	  eﬀec)ve	  —	  is	  probably	  typical	  of	  many	  new	  func)ons.”	  -­‐	  Lemski	  
	  
Genotype	  ≠	  Phenotype	  
Environment	  maXers!	  
Ancestry	  maXers!	  
Genomic	  background	  maXers!	  
Longitudinal	  course	  maXers!	  
	  
Categorical	  Thinking	  Misses	  Complexity	  
A	  conceptual	  model	  of	  genotype-­‐phenotype	  correla;ons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  )me,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctua)ons.	  	  	  
Time	  
Environment	  
Phenotypic	  
Spectrum	  

Cre;nism	  –	  lack	  of	  iodine	  in	  the	  diet,	  leading	  to	  
thyroid	  hormone	  deﬁciency.	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Down	  Syndrome	  
Down	  Syndrome	  
Christopher	  Joseph	  "Chris"	  Burke	  (born	  August	  
26,	  1965)	  is	  an	  American	  actor	  and	  folk	  singer,	  
who	  lives	  with	  Down	  syndrome,	  who	  has	  
become	  best	  known	  for	  his	  character	  Charles	  
"Corky"	  Thacher	  on	  the	  television	  series	  Life	  
Goes	  On.	  
	  
And	  there	  are	  people	  with	  Mosaic	  Down	  
Syndrome,	  who	  are	  much	  less	  aﬀected.	  
Velocardiofacial	  (22q11.2)	  Syndrome	  
“Superpower”	  muta)ons???	  
LRP5	  muta)on	  
D111Y,	  G171R,	  A214T,	  A214V,	  A242T,	  and	  
T253I	  	  	  
Myosta)n	  muta)on	  	  
	  Exon	  2	  allele	  	  P198A	  
**Thanks	  to	  George	  Church	  for	  discussions	  on	  this.	  
Another	  example:	  Liam	  Hoekstra,	  known	  as	  the	  world's	  strongest	  
toddler	  at	  age	  3,	  has	  a	  condi)on	  called	  myosta)n-­‐related	  muscle	  
hypertrophy	  which	  results	  in	  increased	  muscle	  mass	  and	  reduced	  body	  
fat.	  Myosta)n-­‐related	  muscle	  hypertrophy,	  or	  muscle	  enlargement,	  is	  
an	  extremely	  rare	  gene)c	  condi)on.	  –	  How	  rare???	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hours after birth, and the infant was admitted to
the neonatal ward for assessment. He appeared ex-
traordinarily muscular, with protruding muscles
in his thighs (Fig. 1A) and upper arms. With the
exception of increased tendon reflexes, the physi-
cal examination was normal. Hypoglycemia and
increased levels of testosterone and insulin-like
growth factor I were excluded. Muscular hypertro-
phy was verified by ultrasonography when the in-
fant was six days of age (Fig. 1B and 1C). Doppler
echocardiography and electrocardiography per-
formed soon after birth and every six months there-
after were consistently normal. At 4.3 years of age
(body-surface area, 0.78 m
 
2
 
), the child had a pulse
rate of 95 beats per minute, a left ventricular ejection
fraction of 70 percent, fractional shortening at the
midwall of 56 percent, and a cardiac output of 2.81
liters per minute, with a left ventricular measure-
ment of 3.42 cm during diastole (50th percentile)
and 1.99 cm (25th percentile) during systole and
respective septal measurements of 0.59 cm (75th
percentile) and 0.81 cm (75th percentile).
The stimulus-induced myoclonus gradually sub-
sided after two months. The child’s motor and
mental development has been normal. Now, at 4.5
years of age, he continues to have increased muscle
bulk and strength, and he is able to hold two 3-kg
dumbbells in horizontal suspension with his arms
extended.
Several family members (Fig. 1D) have been re-
ported to be unusually strong. Family member II-3
was a construction worker who was able to unload
curbstones by hand. The 24-year-old mother of the
child (III-5) appeared muscular, though not to the
extent observed in her son; she did not report any
health problems. No family members aside from
the mother were available to provide samples for
genetic analysis.
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Figure 1. Photographs of the Child at the Ages of Six Days 
and Seven Months (Panel A), Ultrasonograms (Panel B) 
and Morphometric Analysis (Panel C) of the Muscles 
of the Patient and a Control Infant, and the Patient’s 
Pedigree (Panel D).
 
The arrowheads in Panel A indicate the protruding mus-
cles of the patient’s thigh and calf. In Panel B, an ultra-
sonographic transverse section (linear transducer, 10 
MHz) through the middle portion of the thigh reveals 
differences between the patient and a control infant of 
the same age, sex, and weight. VL denotes vastus latera-
lis, VI vastus intermedius, VM vastus medialis, RF rectus 
femoris, and F femur. In Panel C, retracings of the mus-
cle outlines and results of the morphometric analysis of 
the muscle cross-sectional planes of the two infants also 
reveal marked differences. Panel D shows the patient’s 
pedigree. Solid symbols denote family members who are 
exceptionally strong, according to information in their 
clinical history. Square symbols denote male family 
members, and circles female family members.
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uscle wasting and weakness are among the most common
 
 
 
in-
 
herited and acquired disorders and include the muscular dystrophies,
cachexia, and ag -related wasting. Since there is no generally accepted
treatment to i prove muscle bulk and strength, these conditions pose a substantial
burden to patients as well as to public health. Consequently, there has been consider-
able interest in a recently described inhibitor of muscle growth, myostatin, or growth/
differentiation factor 8 (GDF-8), which belongs to the transforming growth factor 
 
b
 
superfamily of secreted proteins that control the growth and differentiation of tissues
throughout the body. The myostatin gene is expressed almost exclusively in cells of
skeletal-muscle lineage throughout embryonic development as well as in adult ani-
mals and functions as a negative regulator of muscle growth.
 
1,2
 
 Targeted disruption of
the myostatin gene in mice doubles skeletal-muscle mass.
 
1
 
 Conversely, systemic over-
expression of the myostatin gene leads to a wasting syndrome characterized by ex-
tensive muscle loss.
 
3
 
 In adult animals, myostatin appears to inhibit the activation of
satellite cells, which are stem cells resident in skeletal muscle.
 
4,5
 
The potential relevance of myostatin to the treatment of disease in humans has been
suggested by studies involving 
 
mdx
 
 mi e, which carry a mutation in the dystrophin gene
and therefore serve as a genetic model of Duchenne’s and Becker’s muscular dystro-
phy.
 
6
 
 For example
 
, mdx
 
 mice that lacke  myost tin were foun  not only to be stronger
and more muscular than their
 
mdx
 
 counterparts with normal myostatin, but also to have
reduced fibrosis and fatty remodeling, suggesting mproved regeneration of us-
cle.
 
7
 
 Furthermore, injection of neutralizing monoclonal antibodies directed against
myostatin into either wild-type or 
 
mdx
 
 mice increases mus le mass and specific force,
suggesting that myostatin plays an important role in regulating muscle growth in adult
animals.
 
8,9
 
The function of myostatin appears to be conserved across species, since mutations
in the myostatin gene have been shown to be responsible for the “double-muscling”
phenotype in cattle.
 
10-13 
 
The phenotypes of mice and cattle lacking myostatin and the
high degree of sequence conservation of the predicted myostatin protein in many mam-
malian species have raised the possibility that myostatin may help regulate muscle
growth in humans. We report the identification of a myostatin mutation in a child with
muscle hypertrophy, thereby providing strong evidence that myostatin does play an im-
portant role in regulating muscle mass in humans.
A healthy woman who was a former professional athlete gave birth to a son after a nor-
mal pregnancy. The identity of the child’s father was not revealed. The child’s birth
weight was in the 75th percentile. Stimulus-induced myoclonus developed several
m
case report
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Double muscling is a trait previously described in several mammalian species including cattle and sheep and is caused
by mutations in the myostatin (MSTN) gene (previously referred to as GDF8). Here we describe a new mutation inMSTN
found in the whippet dog breed that results in a double-muscled phenotype known as the ‘‘bully’’ whippet. Individuals
with this phenotype carry two copies of a two-base-pair deletion in the third exon ofMSTN leading to a premature stop
codon at amino acid 313. Individuals carrying only one copy of the mutation are, on average, more muscular than wild-
type individuals (p ¼ 7.43 3 10"6; Kruskal-Wallis Test) and are significantly faster than individuals carrying the wild-
type genotype in competitive racing events (Kendall’s nonparametric measure, s¼ 0.3619; p ’ 0.00028). These results
highlight the utility of performance-enhancing polymorphisms, marking the first time a mutation in MSTN has been
quantitatively linked to increased athletic performance.
Citation: Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, et al. (2007) A mutation in the myostatin gene increases muscle mass and enhances racing
performance in heterozygote dogs. PLoS Genet 3(5): e79. doi:10.1371/journal.pgen.0030079
Introduction
The wide variety of behaviors and morphological types
exhibited among dog breeds and the overall low genetic
diversity within each breed make the dog an excellent genetic
system for mapping traits of interest [1,2]. Recently, owners of
whippets, an established racing-dog breed, have reported a
phenotype of heavy muscling occurring within the breed
(http://www.k9community.co.uk/forums/index.php). The typi-
cal whippet is similar in conformation to the greyhound, a
medium-sized sighthound, weighing about 9 kg and charac-
terized by a slim build, long neck, small head, and pointed
snout (Figure 1A) [3]. Heavily muscled dogs, termed ‘‘bully’’
whippets by breeders, have broad chests and unusually well-
developed leg and neck musculature (Figure 1C). ‘‘Bully’’
whippets are easily distinguished from their normal litter-
mates based on physical appearance alone (compare Figure
1A and 1C). Owners report that ‘‘bully’’ whippets do not have
any health abnormalities other than muscle cramping in the
shoulder and thigh. However, the dogs are often euthanized
at an early age as they do not conform to the American
Kennel Club breed standard. In addition, about 50% of
‘‘bully’’ whippets have a distinctive overbite.
The ‘‘bully’’ whippet phenotype is reminiscent of the
double muscling phenotype seen in other species that is
caused by mutations in the myostatin (MSTN) gene. Such
variants have been observed in mice [4], cattle [5,6], sheep [7],
and human, the latter described once in a German boy [8].
The myostatin protein has been shown to affect both the
amount and composition of muscle fibers. For instance, the
muscle mass of Mstn knockout mice is two to three times
greater than that of wild-type mice [9]. Furthermore, the
sequence of the MSTN gene is relatively conserved across
species [9]. Therefore, we chose to interrogate theMSTN gene
for possible mutations resulting in the ‘‘bully’’ whippet
phenotype.
Results
MSTN Genotypes in the Whippet
We sequenced the three exons and the majority of introns
of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
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of the MSTN gene in an initial set of 22 whippets. A 2-bp
deletion was discovered in the third exon of the MSTN gene
(Figure 2). This deletion removes nucleotides 939 and 940
within exon three and leads to a premature stop codon at
amino acid 313 instead of the normal cysteine, removing 63
aa from the predicted 375-aa protein. The lost cysteine is one
of several highly conserved cysteines known to form disulfide
dimers required for protein function [9].
Of the 22 whippets sequenced, all ‘‘bully’’ whippets tested
(n ¼ 4) were homozygous for the deletion (mh/mh) while all
dogs that sired or whelped a ‘‘bully’’ whippet (n ¼ 5) were
heterozygous for the deletion (mh/þ). None of the initial set of
13 normal-appearing whippets that lacked a family history of
the ‘‘bully’’ phenotype carried the deletion; these dogs were
designated wild type (þ/þ). An additional set of DNA samples
from 146 whippets (both racers and nonracers) were collected
at racing events and through the mail without regard to the
dogs’ family histories of the ‘‘bully’’ phenotype. These were
Editor: Joseph S. Takahashi, Northwestern University, United States of America
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Ogden	  Syndrome	  
We	  found	  the	  SAME	  muta)on	  in	  two	  unrelated	  families,	  with	  a	  very	  similar	  
phenotype	  in	  both	  families,	  helping	  prove	  that	  this	  genotype	  contributes	  to	  the	  
phenotype	  observed.	  
First	  boy.	  Called	  “a	  liXle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  ﬁrst	  boy	  in	  the	  late	  1970’s.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  ﬁssures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  ﬂared	  nares,	  hypoplas)c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	  
	  
This	  is	  the	  “Proband”	  photograph	  presented	  at	  Case	  Conference.	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Understanding the spectrum of allelic variation in human genes and 
revealing the demographic and evolutionary forces that shape this varia-
tion within and among populations is a major aim of human genetics 
research. Such information is critical for defining the architecture of 
common diseases, identifying functionally important variation, and ulti-
mately facilitating the interpretation of personalized disease risk profiles 
(1–3). To date, surveys of human variation have been dominated by 
studies of single nucleotide polymorphisms (SNPs) genotyped using 
high-density arrays composed of common variants (4–6). While these 
projects have substantially improved our knowledge of common allelic 
variation and enabled genome-wide association studies (GWAS), they 
have been generally uninformative about the population genetics charac-
teristics of rare variants, defined here as a minor allele frequency (MAF) 
of less than 0.5%. 
Rare genetic variants are predicted to vastly outnumber common 
variants in the human genome (7, 8). By capturing and sequencing all 
protein-coding exons (i.e., the exome, which comprises ~1-2% of the 
human genome), exome sequencing is a powerful approach for discover-
ing rare variation and has facilitated 
the genetic dissection of unsolved 
Mendelian disorders and studying 
human evolutionary history (9–14). 
Rare and low frequency (MAF be-
tween 0.5%-1%) variants have been 
hypothesized to explain a substantial 
fraction of the heritability of common, 
complex diseases (15). Since common 
variants explain only a modest fraction 
of the heritability of most traits (16, 
17), NHLBI recently sponsored the 
multicenter Exome Sequencing Project 
(ESP), to identify novel genes and 
molecular mechanisms underlying 
complex heart, lung, and blood disor-
ders by sequencing the exomes of a 
large number of individuals measured 
for phenotypic traits of substantial 
public health significance (e.g., early-
onset myocardial infarction, stroke, 
body mass index). 
Data generation and variant dis-
covery. A total of 63.4 terabases of 
DNA sequence was generated at two 
centers with three complimentary defi-
nitions of the exome target and two 
different capture technologies (18). We 
sequenced samples from 14 different 
cohorts in the ESP to an average medi-
an depth of 111x (range 23x – 474x). 
We found no evidence of cohort- 
and/or phenotype specific effects, or 
other systematic biases, in the analysis 
of the filtered SNV data (18; Figs. S1-
S7). Exomes from related individuals 
were excluded from further analysis 
(18; Fig. S8) resulting in a dataset of 
2,440 exomes. We inferred genetic 
ancestry using a clustering approach 
(18), and focused the remaining anal-
yses on the inferred 1,351 EA and 
1,088 AA individuals. We subjected 
the 563,698 variants in the intersection 
of all three capture targets to standard 
quality control filters (18) resulting in a final data set of 503,481 single 
nucleotide variants (SNVs) identified in 15,585 genes and 22.38 Mb of 
targeted sequence per individual. We assessed data quality and error 
rates using complementary strategies (18). Approximately 98% 
(941/961) of all variant sites that were experimentally tested were con-
firmed, including 98% (234/238) of singletons, 98% (678/693) of non-
singleton SNV sites with a MAF < 10%, and 97% (29/30) of SNV sites 
ZLWKD0$) 
The vast majority of coding variation is rare and novel. We ob-
served a total of 503,481 SNVs and 117 fixed, non-reference sites, of 
which 325,843 and 268,903 were found in AA and EA, respectively (18; 
Fig. S9A). Excluding singletons, ~58% of SNVs were population-
specific (93,278 and 32,552 variants were uniquely observed in AA, or 
EA, respectively), and the vast majority of these variants were rare (18; 
Fig. S9B). Most SNVs (292,125 or 58%) were nonsynonymous includ-
ing 285,960 missense variants and 6,165 nonsense variants (18; Fig. 
S9C). Synonymous variants accounted for 38% (188,975) of the total 
SNVs (18; Fig. S9C), with the remaining 4% of SNVs (22,381) located 
Evolution and Functional Impact of 
Rare Coding Variation from Deep 
Sequencing of Human Exomes 
Jacob A. Tennessen,1* Abigail W. Bigham,2*† Timothy D. O’Connor,1* Wenqing 
Fu,1 Eimear E. Kenny,3 Simon Gravel,3 Sean McGee,1 Ron Do,4,5 Xiaoming Liu,6 
Goo Jun,7 Hyun Min Kang,7 Daniel Jordan,8 Suzanne M. Leal,9 Stacey Gabriel,4 
Mark J. Rieder,1 Goncalo Abecasis,7 David Altshuler,4 Deborah A. Nickerson,1 
Eric Boerwinkle,6,10 Shamil Sunyaev,4,8 Carlos D. Bustamante,3 Michael J. 
Bamshad,1,2‡ Joshua M. Akey,1‡ Broad GO, Seattle GO, on behalf of the NHLBI 
Exome Sequencing Project 
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USA. 5The Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, 
USA. 6Human Genetics Center, University of Texas Health Sciences Center at Houston, Houston, Texas, 
USA. 7Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA. 8Division of Genetics, 
Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. 9Department of Molecular and 
Human Genetics, Baylor College of Medicine, Houston, TX, USA. 10Human Genome Sequencing Center, 
Baylor College of Medicine, Houston, Texas, USA. 
*These authors contributed equally to this work. 
†Present address: Department of Anthropology, University of Michigan, Ann Arbor, MI, USA. 
‡To whom correspondence should be addressed. E-mail: akeyj@uw.edu (J.M.A.); 
mbamshad@u.washington.edu (M.J.B.) 
As a first step toward understanding how rare variants contribute to risk for 
complex diseases, we sequenced 15,585 human protein-coding genes to an average 
median depth of 111x in 2,440 individuals of European (n=1,351) and African 
(n=1,088) ancestry. We identified >500,000 single nucleotide variants (SNVs), the 
majority of which were rare (86% with a minor allele frequency < 0.5%), novel (82%), 
and population-specific (82%). On average, 2.3% of the 13,595 SNVs each person 
carries were predicted to impact protein function of ~313 genes per genome, and 
~95.7% of SNVs predicted to be functionally important were rare. This excess of rare 
functional variants is due to the combined effects of explosive, recent accelerated 
population growth and weak purifying selection. Furthermore, we show that large 
sample sizes will be required to associate rare variants with complex traits. 
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Crohn’s disease and ulcerative colitis are classified as chronic, idi-
opathic inflammatory bowel diseases (IBDs) of the gastrointestinal 
tract with unknown etiology (MIM266600). Crohn’s disease occurs 
in about 100–150 per 100,000 individuals of European a cestry1. 
Generally, the disease affects the ileum and colon, but it can affect any 
region of the gut. Ulcerative colitis has similar population prevalence, 
and although it has some similarities to Crohn’s disease in clinical 
manifestation, the location of inflammation is limited to the colonic 
mucosa. Strong familial aggregation has been observed in twin studies 
of Crohn’s disease and ulcerative colitis2,3. Recent population-based 
sibling risk is 26-fold greater for Crohn’s diseas  and 9-fold greater for 
ulcerative colitis2, and overall Crohn’s disease and ulcerative colitis 
concordance rates in nonselected twin studies are 30% and 15%, 
respectively, among monozygotic twins compared with 4% for 
Crohn’s disease or ulcerative colitis among dizygotic twins3. Like most 
complex diseases, Crohn’s disease and lcerative colitis result from 
a combination of genetic and nongenetic risk factors, and each 
individual factor probably has a modest effect on disease risk4.
Deep resequencing of GWAS loci identifies independent 
rare variants associated with inflammatory bowel disease
Manuel A Rivas1–3, Mélissa Beaudoin4,23, Agnes Gardet5,23, Christine Stevens2,23, Yashoda Sharma6,  
Clarence K Zhang6, Gabrielle Boucher4, Stephan Ripke1,2, David Ellinghaus7, Noel Burtt2, Tim Fennell2,  
Andrew Kirby1,2, Anna Latiano8, Philippe Goyette4, Todd Green2, Jonas Halfvarson9, Talin Haritunians10,  
Joshua M Korn2, Finny Kuruvilla2,11, Caroline Lagacé4, Benjamin Neale1,2, Ken Sin Lo4, Phil Schumm12,  
Leif Törkvist13, National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease 
Genetics Consortium (NIDDK IBDGC)14, United Kingdom Inflammatory Bowel Disease Genetics Consortium14, 
International Inflammatory Bowel Disease Genetics Consortium14, Marla C Dubinsky15, Steven R Brant16,17, 
Mark S Silverberg18, Richard H Duerr19,20, David Altshuler1,2, Stacey Gabriel2, Guillaume Lettre4, Andre Franke7, 
Mauro D’Amato21, Dermot P B McGovern10,22, Judy H Cho6, John D Rioux4, Ramnik J Xavier1,2,5 & Mark J Daly1,2
More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; 
however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here 
we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn’s disease in 350 cases and 350 
controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control 
series (16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional 
independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant associa i n with a protective 
splice varia t in CARD9 (P < 1 × 10−16, odds ratio y 0.29) and additional associations with coding variants in IL18RAP, CUL2, 
C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional 
variants that could aid functional experiments and predictive models.
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SUMMARY
While it is known that rare copy-number variants
(CNVs) contribute to risk for some neuropsyc iatric
disorders, the role of CNVs in bipolar disorder is
unclear. Here, we reasoned that a contribution of
CNVs to mood disorders might be most evident for
de novo mutations. We performed a genome-wide
an lysis of de novo CNVs in a cohort of 788 rios.
Diagnoses of offspring included bipolar disorder
(n = 185), schizophre ia ( = 177), and healthy
controls (n = 426). Frequencies of de novo CNVs
were significantly higher in bipolar disorder as com-
pared with controls (OR = 4.8 [1.4,16.0], p = 0.009).
De novo CNVs were particularly enriched among
cases with an age at onset younger than 18 (OR =
6.3 [1.7,22.6], p = 0.006). We also confirmed a signifi-
cant enrichment of de novo CNVs in schizophrenia
(OR = 5.0 [1.5,16.8], p = 0.007). Our results suggest
that rare spontaneous mutations are an important
contributor to risk for bipolar diso der and other
major neurop ychiatric diseases.
INTRODUCTION
Bipolar disorder (BD, also known s a ic-depressive illness) is
a severe ood disord r onsisti g of episodes of mania and
epression. The lifetime prevalence of bipolar disorder in the
gen ral population is !1% and the illness i associated with
consid rable morbidity and a high lif time isk of suicide (Meri-
kangas et al., 2011).
Genes play an important r le in risk for BD. Th rate of concor-
dance formonozygotic twins is 40%, comparedwith a 5% rate in
dizygotic twins (Kendler et al., 1995; Kieseppa¨ et al., 2004;
McGuffin et al., 2003), and risk among the first-degree relatives
of individuals with BD is ten-fold greater than risk among the
general population (Barnett and Smoller, 2009). However, as
with other psychiatric disorders, the genetics of BD is complex,
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Recent advances in sequencing technology are making possible the application of large-scale genomic anal-
yses to individualized care, both in wellness and disease. However, a number of obstacles remain before ge-
nomic sequencing can become a routine part of clinical practice. One of the more signiﬁcant and
underappreciated is the lack of consensus regarding the proper environment and regulatory structure
under which clinical genome sequencing and interpretation should be performed. The continued reliance
on pure research vs. pure clinical models leads to problems for both research participants and patients in
an era in which the lines between research and clinical practice are becoming increasingly blurred. Here,
we discuss some of the ethical, regulatory and practical considerations that are emerging in the ﬁeld of geno-
mic medicine. We also propose that many of the cost and safety issues we are facing can be mitigated through
expanded reliance on existing clinical regulatory frameworks and the implementation of distributive
work-sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive
teams.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
We are entering a fascinating and uncertain period of medical his-
tory, as today's DNA sequencing technology has the potential to help
each of us direct our care and predict our future based on knowledge
of our own individual inherited and acquired genetics. However,
from a global and local economic perspective, these are lean years,
and this adds a signiﬁcant degree of uncertainty to the immediate fu-
ture of this enterprise. It is therefore incumbent upon us to show that
the personalized medical application of large-scale genomic analysis
will not just be a luxury or a burdensome cost center, but that it
truly has the potential to save both lives and health care expenses
via data-driven management, early disease detection/screening and
more efﬁcacious pharmaceutical delivery. To this end, we need to de-
termine how to move forward towards expanded clinical use of this
technology in a manner both rapid and economical, while ensuring
the integrity of the process and the safety and well-being of patients
and research participants. This will require careful thought and con-
sideration regarding the proper environment and regulatory structure
surrounding genomics, as well as the development of consensus re-
gardingwhat exactly constitutes a genetic test in the age of large-scale
genomics and informatics.
2. Paving the way for the broad implementation of clinical
genomic medicine
A report published in 2011 by the National Research Council for
the National Academy of Sciences elegantly described the major divi-
sions between the clinical and research worlds, including in regards
to large-scale genomic analyses, such as whole genome (WGS) se-
quencing. The report went on to offer suggestions for how to help
merge these two worlds, including articulating the need for a “Knowl-
edge Network” and “New Taxonomy”, with the recommendation that
pilot studies along such lines should be conducted (Anon., 2011).
However, the report did not address a critical issue related to genetic
testing, namely the rules that should govern genomic research and
clinical care as we move into the coming era of individualized medi-
cine. The United States federal government mandates that any labora-
tory performing tests on human specimens “for the purpose of
providing information for the diagnosis, prevention, or treatment of
any disease”must satisfy the conditions set forth in the Clinical Labo-
ratory Improvement Amendments (CLIA) of 1988 (Group®, 2012).
Applied & Translational Genomics xxx (2013) xxx–xxx
Abbreviations: CLIA, Clinical Laboratory Improvements Amendments; NGS, Next
generation sequencing; WGS, whole-genome sequencing.
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•  Seguin	  E.	  1866,	  -­‐	  	  “our	  incomplete	  studies	  do	  
not	  permit	  actual	  classiﬁca)on;	  but	  it	  is	  beXer	  
to	  leave	  things	  by	  themselves	  rather	  than	  to	  
force	  them	  into	  classes	  which	  have	  their	  
founda)on	  only	  on	  paper”-­‐	  from	  Idiocy	  and	  its	  
treatment	  by	  the	  physiological	  method.	  
•  Walter	  Frank	  Raphael	  Weldon	  1902	  –	  “the	  
accumula)on	  of	  records,	  in	  which	  results	  are	  
massed	  together	  in	  ill-­‐deﬁned	  categories	  of	  
variable	  and	  uncertain	  extent,	  can	  only	  result	  
in	  harm”.	  
OBSERVATIONS ON AN ETHNIC CLASSIFICATION OF IDIOTS *
J. LANGDON H. DOWN M.D., London
THOSE who have given any attention to congenital mental lesions, must have
been frequently puzzled how to arrange, in any satisfactory way, the different
classes of this defect which may have come under their observation. Nor
will the difficulty be lessened by an appeal to what has been written on the
subject. The systems of classification are generally so vague and artificial,
that, not only do they assist but feebly, in any mental arrangement of the
phenomena which are presented, but they completely fail in exerting anypractical influence on the subject.
The medical practitioner who may be consulted in any given case, has,
perhaps in a very early condition of the child's life, to give an opinion on
points of vital importance as to the present condition and probable future of
the little one. Moreover, he may be pressed as to the question, whether the
supposed defect dates from any cause subsequent to the birth or not. Has
the nurse dosed the child with opium? Has the little one met with any
accident? Has the instrumental interference which maternal safety de-
manded, been the cause of what seems to the anxious parents, a vacant future?
Can it be that when away from the family attendant the calomel powders
were judiciously prescribed? Can, in fact, the strange anomalies which the
child presents, be attributed to the numerous causes which maternal solici-
tude conjures to the imagination, in order to account for a condition, for
which any cause is sought, rather than hereditary taint or parental influence.
Will the systems of classification, either all together, or any one of them,
assist the medical adviser in the opinion he is to present, or the suggestions
which he is to tender to the anxious parent? I think that they will entirely
fail him in the matter, and that he will have in many cases to make a guarded
diagnosis and prognosis, so guarded, in fact, as to be almost valueless, or to
venture an authoritative assertion which the future may perhaps confirm.
I have for sometime had my attention directed to the possibility of
making a classification of the feeble minded by arranging them around
various ethnic standards—in other words, framing a natural system to
supplement the information to be derived by an inquiry into the history of
the case.
I have been able to find among the large number of idiots and imbeciles
which come under my observation, both at Earlswood and the out-patient
department of the Hospital, that a considerable portion can be fairly re-
ferred to one of the great divisions of the human family other than the class
from which they have sprung. Of course, there are numerous representatives
of the great Caucasian family. Several well-marked examples of the Ethi-
opian variety have come under my notice, presenting the characteristic
malar bones, the prominent eyes, the puffy lips, and retreating chin. The
* This paper from the London Hospital Clinical Report 3, 259-262 (i866) is republishedon account of its historical interest (see page 698). The editors are indebted to Dr J. H.
Edwards, The Medical School, University of Birmingham who proposed republication and
provided the copy.
695
NOTES AND COMMENTS 697
The life expectancy, however, is far below the average, and the tendency is
to the tuberculosis, which I believe to be the hereditary origin of the
degeneracy.Apart from the practical bearing of this attempt at an ethnic classification,
considerable philosophical interest attaches to it. The tendency in the
present day is to reject the opinion that the various races are merely varieties
of the human family having a common origin, and to insist that climatic,
or other influences, are insufficient to account for the different types of man.
Here, however, we have examples of retrogression, or at all events, of de-
parture from one type and the assumption of the characteristics of another.
If these great racial divisions are fixed and definite, how comes it that disease
is able to break down the barrier, and to simulate so closely the features os
the members of another division. I cannot but think that the observations
which I have recorded are indications that the differences in the races are not
specific but variable.
These examples of the result of degeneracy among mankind, appear to me
to furnish some arguments in favour of the unity of the human species.
London Hospital Cli ical Lecture Report. 3, 259-262, i866.
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“Those	  who	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  given	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  under	  their	  observa)on.	  Nor	  will	  the	  diﬃculty	  be	  
lessened	  by	  an	  appeal	  to	  what	  has	  been	  wriXen	  on	  the	  subject.	  
The	  systems	  of	  classiﬁca)on	  are	  generally	  so	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  and	  ar)ﬁcial,	  
that,	  not	  only	  do	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  assist	  but	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  any	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  of	  the	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  represented,	  but	  they	  
completely	  fail	  in	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  inﬂuenc 	  on	  the	  subject.”	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Medical genetics typically entails the detailed characterization of a patient’s phenotypes followed
by genotyping to discover the responsible gene or mutation. Here, we propose that the systematic
discovery of genetic variants associatedwith complex diseases such as autism are progressing to a
point where a reverse strategy may be fruitful in assigning the pathogenic effects of many different
genes and in determining whether particular genotypes manifest as clinically recognizable pheno-
types. This ‘‘genotype-first’’ approach for complex disease necessitates the development of large,
highly integrated networks of researchers, clinicians, and patient families, with the promise of
improved therapies for subsets of patients.
The genetic study of complex disease has
historically been difficult, meeting with
limited success and often even fewer
therapeutic advances in patient care. Un-
like Mendelian disorders, complex dis-
ease is defined as a phenotype that is
not caused by a single gene mutation
but, rather, by many individual gene
events, with a significant contribution
from environmental factors. The nature
of complex genetic diseasemakes patient
care difficult, as a clinician may never see
two individuals with the same gene muta-
tion and, therefore, the same underlying
genetic etiology. Classical approaches
to the study of complex disease have
identified patientswith similar phenotypes
and have attempted to identify the com-
mon causative mutation for this pheno-
type using association studies. Though
there have been numerous loci reported
over the last 10 years, in most cases,
much of the heritability of complex dis-
ease remains unresolved (Manolio et al.,
2009). The number of success stories
for complex neurocognitive and neuro-
behavioral disease are even fewer, with
enormous numbers of patients (>30,000)
being required to discover a small fraction
of the genetic risk using genome-wide
association study (GWAS) approaches
(McCarroll and Hyman, 2013). Complex
neurodevelopmental disorders, such as
autism, schizophrenia, bipolar disorder,
intellectual disability (ID), and devel-
opmental delay (DD), require better
approaches to link genotype to pheno-
type. In this Essay, we focus on autism
spectrum disorder (ASD)—a highly com-
plex neurodevelopmental disease with a
range of phenotypes and a large patient
base—and propose a gene-centric meth-
odology to model a streamlined approach
for subtyping autism starting with the
genotype (Schulze and McMahon, 2004).
The explosion of data from recent
exome studies (Iossifov et al., 2012; Neale
et al., 2012; O’Roak et al., 2012b; Sanders
et al., 2012) and earlier work on large copy
number variants (CNVs) (de Vries et al.,
2005; Sebat et al., 2007; Sharp et al.,
2006) have emphasized the importance
of sporadic truncating mutations in ASD,
revealing a surprising level of genetic het-
erogeneity among patients. From these
data, it has been estimated that >500
distinct loci may be related to disease
etiology in ASD, assuming a model of
sporadic protein-encoding mutations.
Interestingly, more than two decades
ago, Percy postulated that a ‘‘very wide
variety of autistic syndromes depending
on underlying etiology’’ may exist based
on his observation that a significant frac-
tion of individuals with fragile X, Rett,
and tuberous sclerosis syndromes could
be classified as having autistic features
(Percy et al., 1990). Whereas traditional
genetics approaches were entirely under-
powered to detect small subpopulations
of autism with a common mutant gene,
the advent of next-generation sequencing
technology has made it possible to begin
to systematically classify genetic sub-
types of ASD and, further, to ask whether
these define specific clinical subtypes of
ASD. For the purpose of this Essay, we
will define a ‘‘genetic subtype’’ as a gene
in which recurrent mutations show an
excess of burden in patients versus con-
trols. This is distinguished from a ‘‘molec-
ular subtype’’ that constitutes a group of
genetic subtypes that are linked together
in a common pathway (coexpression,
protein-protein interaction network, etc.)
(O’Roak et al., 2012b).
The extreme genetic heterogeneity
exemplified by autism, we believe, re-
quires a shift in the approach to studying
the genetics of complex neurological
disease. Instead of comprehensive and
exhaustive phenotyping as the first step
to reducing genetic heterogeneity, we
propose to leverage technology to genet-
ically classify subtypes of disease among
patients in whom clinical recontact is
possible. We outline three logical steps
in characterizing genetic subtypes from
the perspective of autism: (1) candidate
discovery and determination of pathoge-
nicity, (2) comprehensive clinical pheno-
typing, and (3) resolution of genetic
872 Cell 156, February 27, 2014 ª2014 Elsevier Inc.
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random mutation modeling40 to calculate the likelihood that observed 
(de novo) mutations have a damaging effect. Similar prioritizations 
are provided by tools that score individual mutation severity (SIFT, 
PolyPhen2, MutationTaster, MutPred, CONDEL, etc.), some of which 
can be adapted to a gene-based prioritization score from genome-wide 
data41. These population data provide a powerful unbiased approach 
to home in on genes that are likely to be among the most penetrant 
because of the complete absence of disruptive variation in the general 
population (for example, CHD8 or DYRK1A). A critical aspect of such 
analyses is the reliability of a particular gene model. Most human 
genes show evidence of alternative splice forms, many of which have 
no known function. Apparent hotspots of mutation for a particular 
exon (often exon-intron boundaries) in both cases and controls may 
suggest misannotation, the presence of a processed pseudogene or an 
alternative, nonfunctional splice form.
Pathway enrichment and links to cancer biology
Another popular approach to discern the most important gene 
candidates for further disease association and characterization has 
been to identify specific biological networks of genes enriched in 
cases as compared to controls. Although this approach cannot be used 
unequivocally to define causality, membership of a specific gene in a 
particular protein-protein interaction (PPI) or coexpression network 
may increase the likelihood of its association with disease. Numerous 
studies have reported significant enrichment of both de novo 
CNV and single-nucleotide variant (SNV) mutations in particular 
pathways3,4,42,43. O’Roak et al.3, for example, reported a significant 
enrichment of de novo disruptive autism mutations among proteins 
associated with chromatin remodeling and B-catenin and WNT 
signaling—a finding that was replicated in a follow-up resequencing 
study of more than 2,400 probands. One recent instance, in which 
membership of a new candidate gene in a PPI network led to the 
discovery of an autism-associated gene, is ADNP. A single ADNP 
LoF mutation was initially observed in exome sequencing studies. 
Although the observed mutation frequency in this gene did not reach 
statistical significance when cases and controls were compared20, 
it was strongly implicated in the PPI network originally defined 
by O’Roak et al.3 Targeted resequencing experiments combined 
with clinical exome sequencing identified several more cases with 
de novo mutations and remarkably similar phenotypes represent-
ing a new SWI-SNF–related autism syndrome (Fig. 3)44. Notably, 
many of the genes implicated in the B-catenin pathway have also been 
described as mutated in patients with ID1 but not in patients with 
SCZ. Similarly, an enrichment of genes interacting with FMR1 (also 
known as FMRP)—the gene responsible for fragile X syndrome—has 
been reported with de novo mutations in ASD5, epilepsy11 and, most 
recently, SCZ10,45. Whether this observation is due to the relative high 
incidence of cases that also presented with comorbid ID remains to 
be determined.
In addition to PPI networks, studies of coexpression have shown 
enrichment for specific spatio-temporal patterns of expression. 
A study of coexpressed genes affected by de novo mutations reported 
an enrichment in fetal prefrontal cortical network in SCZ8, which is 
in line with the finding by Xu et al.9 that genes with higher expression 
Table 4 Recurrent identical de novo mutations in 6 genes identified in 11 exome studies with different neurodevelopmental phenotypes
Gene Coding effect Mutation (genomic DNA level) Mutation (cDNA level)
Mutation  
(protein level) Study Disorder
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser de Ligt et al.1 ID
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
ALG13 Missense ChrX(GRCh37):g.110928268A>G NM_001099922.2:c.320A>G p.Asn107Ser Allen et al.11 EE
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Rauch et al.2 ID
KCNQ3 Missense Chr8(GRCh37):g.133192493G>A NM_001204824.1:c.328C>T p.Arg110Cys Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
SCN1A Splice donor LRG_8:g.24003G>A NM_006920.4:c.602+1G>A p.? Allen et al.11 EE
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Rauch et al.2 ID
CUX2 Missense Chr12(GRCh37):g.111748354G>A NM_015267.3:c.1768G>A p.Glu590Lys Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
SCN2A Missense Chr2(GRCh37):g.166198975G>A NM_021007.2:c.2558G>A p.Arg853Gln Allen et al.11 EE
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Neale et al.7 ASD
DUSP15 Missense Chr20(GRCh37):g.30450489G>A NM_080611.2:c.320C>T p.Thr107Met Fromer et al.10 SCZ
EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia.
Figure 1 Genes with recurrent de novo mutations in four 
neurodevelopmental disorders. (a) We estimate the number of fully penetrant 
genes that can explain disease once mutated, based on a de novo model 
using the ‘unseen species problem’. We consider all recurrent missense or 
LoF de novo mutations pathogenic, as well as a defined fraction of mutations 
in genes observed just once (because it is unlikely that all de novo mutations 
are pathogenic). The ratio between genes mutated recurrently and the rate 
of singleton mutations suggests an estimate for the true number of genes 
pathogenic when mutated. Including more singleton mutations increases 
the fraction of each disorder explained by single de novo SNVs at the cost 
of including more genes as pathogenic. Initial exome sequencing studies of 
epilepsy and ID focused on specific pediatric subtypes or the most severe 
cases; thus, the number of generalized epilepsy- or ID-associated genes is 
likely to be much higher. EE, epileptic encephalopathies; ASD, autism spectrum disorder; ID, intellectual disability; SCZ, schizophrenia. (b) Expected  
hit rate (or sensitivity) of true positive genes discovered using trio sequencing studies (under a family-wise error rate of 5%; that is, each gene passes exome-
wide significance of 2.6 × 10−6). We estimate the power of trio sequencing to detect statistically significant associations for disease-associated genes,  
under the assumption that 10% or 20% of singleton mutations could be fully penetrant (vertical bars in a). We assume the distribution of these genes is 
uniform within each disorder and that they do not differ significantly from all genes in terms of length and mutability, although these are taken into account 
when determining significance.
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Recent exome (and genome) sequencing studies of families have aimed 
to comprehensively discover genetic variation to identify the most 
likely causal mutation in patients with disease. Sequencing studies of 
parent-proband trios for probands with intellectual disability (ID)1,2, 
autism spectrum disorder (ASD)3–7, schizophrenia (SCZ)8–10 and epi-
lepsy11 have all suggested that de novo point mutations are important 
in pediatric and adult disorders of brain development (Table 1). The 
relative contribution of de novo mutations to each disorder remains to 
be determined but appears to correlate well with the degree of reduced 
fitness or fecundity of the given condition12. However, not only 
de novo events but also rare inherited copy number variants (CNVs) 
can have an effect on fecundity, though their overall effect on fecundity 
is still debated13. Biologically, 75–80% of de novo point mutations arise 
paternally3,14, likely as a result of the greater number of cell divisions 
in the male germline lineage than in the female lineage. These findings 
are consistent with some epidemiological data that find advancing 
paternal age to be a significant predictor of ASD, ID and SCZ15–17 and 
argue for the need to properly control for paternal age when comparing 
mutation rates between probands and siblings. The importance of 
de novo and private rare mutations is especially important clinically, 
as there are now reports of diagnostic yields ranging from 10–55%  
for select (usually the most severe) groups of patients with ID1,2 and 
epilepsy18, in addition to resolution of unsolved Mendelian disorders19. 
It is clear that next-generation sequencing approaches have provided 
powerful tools for identifying genes harboring potentially pathogenic 
mutations. Deciding which genes to pursue, however, is not always 
self-evident because follow-up research and diagnostic studies are 
critical to understanding the full contribution of a particular mutation 
to its respective phenotype.
In this Review, we will discuss the prioritization of candidate genes 
identified through sequencing studies, show emerging trends and 
highlight potential strategies for subsequent functional characteriza-
tion of these neurodevelopmental genes. We focus on lessons learned 
from 11 recent studies that report 2,368 de novo mutations from a 
total of 2,358 probands and 600 de novo mutations from 731 controls 
(Table 1). The bulk of the data originate from sequencing studies 
of parents and probands with ASD, ID and epileptic encephalopa-
thies, but more recent studies have also highlighted the importance of 
de novo mutations in SCZ. There is evidence that de novo mutations, 
particularly disruptive mutations, occur in the same genes despite the 
nosological distinction for these different diseases. For the purpose of 
this Review, we collectively term these diseases ‘neurodevelopmental 
disorders’ but recognize that some, especially adult-onset diseases 
such as SCZ, may have etiologic components that are not neurode-
velopmental in origin.
Recurrently mutated genes
One of the frequently used concepts in considering possible ‘new 
disease genes’ responsible for a given neurodevelopmental pheno-
type is the recurrence of de novo mutations in the same gene, along 
with the absence of such mutations in healthy controls. This rule 
follows the precedent established for the discovery of pathogenic 
de novo CNVs during the last decade, with the highest priority 
given to recurrent mutations that lead to a complete loss of func-
tion of one of the parental copies of the gene. Up to ten independ-
ent reports of de novo mutations in SCN2A and nine independent 
reports of de novo mutations in SCN1A and STXBP1 have been 
described (Tables 2 and 3). Strikingly, de novo mutations in those 
genes have so far been found exclusively in probands and never in 
controls. Simulation data suggest that at least two but certainly three 
or more recurrent de novo loss-of-function (LoF) events (that is, 
predicted nonsense, frameshift or canonical splice site mutations) 
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Prioritization of ne rodevelopmental disease 
genes by discovery of new mut tions
Alexande  Hoischen1, Niklas Krumm2 & Evan E Eichler2,3
Advances in genome sequencing technologies have begun to revolutionize neurogenetics, allowing the full spectrum of genetic 
variation to be better understood in relation to disease. Exome sequencing of hundreds to thousands of samples from patients 
with autism spectrum disorder, intellectual disability, epilepsy and schizophrenia provides strong evidence of the importance of 
de novo and gene-disruptive events. There are now several hundred new candidate genes and targeted resequencing technologies 
that allow screening of dozens f genes in tens of thousa ds of individuals with h gh specificity and sensitivity. The de ision 
of which genes to pursue depends on many factors, including recurrence, previous evidence of overlap with pathogenic copy 
number variants, the position of the mutation in the protein, the mutational burden among healthy individuals and membership 
of the candidate gene in disease-implicated protein networks. We discuss these emerging criteria for gene prioritization and the 
potential impact on the field of neuroscience.
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in early fetal life have substantial contribu-
tion to SCZ by de novo mutations. Similarly, 
Willsey et al.46 working with a few high- 
confidence sets of ASD-associated genes as 
seeds reported a convergence of the expres-
sion of these genes in deep-layer cortical 
projection neurons (layers 5 and 6) in mid-
fetal development. Another analysis using a 
larger set of ASD and ID risk genes suggested translational regulation 
by FMR1 and an enrichment in superficial cortical layers43. Implicit 
in these types of analyses is the notion that, while more than 1,000 
genes may be responsible for ASD or ID, in the end the genes will con-
verge on a few highly enriched networks of related genes. It is possible 
that molecular therapies targeted to the network at a specific stage of 
development, as opposed to the individual gene, may be beneficial to 
specific groups of patients.
Related to this, it is intriguing that several recurring genes and 
pathways that have been implicated in neurodevelopmental disease 
have also been associated with different forms of cancer (Fig. 4)47. 
While clear-cut examples such as the mutation of the tumor sup-
pressor genes PTEN (Cowden syndrome) or ARID1B (Coffin-Siris 
syndrome) in neurodevelopmental disease have been extensively 
reviewed48, more recent exome sequencing data from patients with 
neurodevelopmental disease suggest new links. The most striking 
observation here is the identical point mutations reported to cause 
cancer when mutated somatically and severe neurodevelopmental syn-
dromes when mutated in the germline. Examples include the identical 
mutations in SETBP1 (ref. 32), ASXL1 (ref. 49) and EZH2 (ref. 50), as 
well as several genes of the RAS–MAP kinase pathway associated with 
parental-age-effect Mendelian disorders51 (Supplementary Table 1). 
It is important to stress that this is an observation at an individual 
gene level and should not be translated to an epidemiological link: 
that is, this cannot be generalized to speculate that patients with neuro-
developmental disorders in these specific genes will all be at a higher 
risk for certain cancer types. Instead, it is likely that this convergence 
represents a selection of genes that are fundamental to cell biology 
(for example, cell proliferation and/or membership in multi-subunit 
complexes associated with chromatin remodeling). There is also the 
distinct possibility of pleiotropy; that is, the genes and pathways have 
completely unrelated functions, explaining developmental defects and 
cancer independently. Therefore, de novo mutations in those genes 
can result in different outcomes depending on timing, genetic back-
ground and cellular context. Nevertheless, there may be advantages 
to integrating sequence data from patients with neurodevelopmental 
disease and massive sequencing programs devoted to the discovery of 
somatic mutations in tumors—for example, the International Cancer 
Genome Project52. It is possible that these intersections will help to 
further prioritize genes important in both cellular development and 
neurodevelopment.
Phenotypic similarity of recurrent de novo mutations
Although essential, statistical support of recurrent mutations is 
not the sole arbiter in determining pathogenicity of particular 
mutations and genes. In particular, it is important to consider the 
phenotypic presentation and overlap of the individuals with the same 
presumptive underlying genetic lesion. In this regard, we note that 
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Figure 2 CNV and exome intersections define 
candidate genes. (a,b) Deletion (red) and 
duplication (blue) burden for developmental 
delay or ID cases and controls for two genes, 
DYRK1A (a) and MBD5 (b), as compared to 
sporadic LoF mutations on the basis of exome 
sequencing of 209 autism simplex trios. DYRK1A 
is a strong candidate gene for cognitive deficits 
associated with Down syndrome; LoF mutations 
are associated with minibrain phenotype in 
Drosophila65, autism-like behavior in mouse64 
and a deletion syndrome in humans27,63. MBD5 
has been implicated as the causal gene for 
the 2q23.1 deletion syndrome associated with 
epilepsy, autism and ID91,92.
a bFigure 3 Phenotypic similarity of two patients 
with identical PACS1 de novo mutations and two 
patients with similar ADNP mutations. (a) These 
two unrelated patients show identical de novo 
point mutations (c.607C>T; p.Arg203Trp) in 
PACS1 (RefSeq NM_018026.3)53. The striking 
similarity in phenotype includes low anterior 
hairline, highly arched eyebrows, synophrys, 
hypertelorism with downslanted palpebral 
fissures, long eyelashes, a bulbous nasal tip, a 
flat philtrum with a thin upper lip, downturned 
corners of the mouth and low-set ears. Reprinted 
from ref. 53, Copyright (2012), with permission from The American Society of Human Genetics. (b) These two unrelated patients both show LoF mutations 
in ADNP (c.2496_2499delTAAA; p.Asp832Lysfs*80 and c.2157C>G; p.Tyr719*)44 resulting in a new SWI-SNF–related autism syndrome. Patients present 
with clinical similarities, including a prominent forehead, a thin upper lip and a broad nasal bridge. Reprinted from ref. 44.
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CNVs collectively have an appreciable impact on human mental 
health, but their large size often precludes specifying the underlying 
genes involved in the disorder. The pathogenicity of many CNVs 
observed in the clinic is unknown because the typical variant is also 
extremely rare, requiring large surveys to achieve significance in 
case-control cohorts1–4. Large-scale analyses of clinical microarray 
data from children with developmental delay, intellectual disability 
and autism spectrum disorder (ASD) are now possible and have 
been used to catalog regions of human dosage imbalance. In most 
cases, multiple candidate genes still underlie the smallest region of 
overlap. In contrast, exome sequencing studies of parent-child trios 
provide the necessary specificity to discover de novo truncating 
mutations—that is, nonsense and frameshift indel mutations—with 
gene-level specificity5–14. Because of the extreme locus heteroge-
neity of such diseases, however, relatively few recurrences have 
been reported, as surveys of tens of thousands of exomes are still 
prohibitively expensive. As large-scale deletions and truncating 
mutations result in the same dosage imbalance for critical genes, 
we reasoned that systematically integrating both classes of muta-
tion would improve power in discovering genes associated with 
developmental delay. Here we have constructed one of the larg-
est CNV morbidity maps of individuals with intellectual disability, 
developmental delay and/or ASD, both as a clinical resource for 
pathogenic CNVs and also to identify genes potentially sensitive 
to dosage imbalance. We then integrated these data with published 
exome sequencing data and used next-generation sequencing 
methods to rapidly resequence candidate genes in individuals 
with unexplained developmental delay. Using this approach, we 
identified pathogenic mutations in new genes with both statistical 
significance and clinical relevance.
Refining analyses of copy number variation identifies 
specific genes associated with developmental delay
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Copy number variants (CNVs) are associated with many neurocognitive disorders; however, these events are typically  
large, and the underlying causative genes are unclear. We created an expanded CNV morbidity map from 29,085 children  
with developmental delay in comparison to 19,584 healthy controls, identifying 70 significant CNVs. We resequenced 26 
candidate genes in 4,716 additional cases with developmental delay or autism and 2,193 controls. An integrated analysis of  
CNV and single-nucleotide variant (SNV) data pinpointed 10 genes enriched for putative loss of function. Follow-up of a subset  
of affected individuals identified new clinical subtypes of pediatric disease and the genes responsible for disease-associated 
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disease despite extensive genetic heterogeneity.
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to that expected with intersections by random chance (OR = 1.15, 
95% confidence interval (CI) = 0.8–1.6; P = 1, Fisher’s exact test). 
However, when we limited our analysis to the 21 genes with 2 or 
more truncating mutations in probands, we observed significant dele-
tion enrichment for 33.3% of the genes (7 of 21 genes; OR = 2.72; 
P = 0.034, Fisher’s exact test), supporting the notion that integrat-
ing CNV data and exome sequencing data increases power to detect 
disease-related genes. Using a statistical framework based on a hyper-
geometric distribution, we computed a joint probability of putative 
loss of function (Online Methods), combining the CNV data with 
the SNV data for the 6,500 individuals from the Exome Sequencing 
Project (ESP) (ESP6500 controls) and published de novo loss-of- 
function mutations in probands. This analysis highlighted 38 of the 
247 genes with nominally significant increases in loss-of-function 
events in cases in comparison to controls (19 with q value a 0.01), 
including 13 genes previously identified as disease causing (Online 
Mendelian Inheritance in Man, OMIM) (Table 2).
Targeted resequencing of candidate genes in ASD and 
intellectual disability
On the basis of the analyses above, we selected a set of 26 candidate 
genes with significant CNV enrichment, rare focal CNVs with de novo 
mutations from exome sequencing studies and top candidates from 
targeted resequencing in ASD and/or intellectual disability (Table 3). 
For three of these regions, we selected at least two adjacent genes map-
ping within the SRO; we also selected six genes (GRIN2B, ARID1B, 
MBD5, PTEN, SCN1A and KANSL1) known to be associated with 
ASD and/or intellectual disability as positive controls30–35. We used 
molecular inversion probe (MIP)-based capture36 to sequence the 26 
genes in 3,387 cases of intellectual disability and/or developmental 
Table 2 Intersection of CNV and exome data
Gene Isoform
Exome data Array CGH
Combined  
LoF P value
Combined  
LoF q valuee
1,879  
published  
cases LoF
1,879 published 
cases de novo 
LoF (ESP average 
read depth >20, 
Dustmasked)
6,500 ESP LoF 
(ESP average 
read depth >20, 
Dustmasked)
Signature  
deletions  
(n = 29,085)
Control  
deletions  
(n = 19,584)
ANK2a NM_020977.3b 1 1 0 5 0 0.0171 0.169
ARHGAP5 NM_001030055.1 1 1 0 7 0 0.0061 0.0833
BCL11A NM_022893.3 1 0 0 4 0 0.0286 0.244
CAPRIN1 NM_005898.4 1 1 0 4 0 0.0286 0.244
CARKD NM_001242881.1c 1 1 0 12 4 0.0363 0.28
CHD2a NM_001271.3 3 3 0 0 0 0.0113 0.127
CHD8a NM_001170629.1 3 3 0 2 0 0.00402 0.0703
CSDE1 NM_001130523.2 1 1 0 3 0 0.0479 0.311
CUL3a NM_003590.4 2 2 0 5 0 0.00383 0.0703
DLL1 NM_005618.3 1 0 0 32 1 2.17 × 10−7 2.68 × 10−5
DYRK1Aa NM_001396.3 2 2 0 11 0 1.74 × 10−4 8.60 × 10−3
FAM8A1 NM_016255.2 1 1 0 5 0 0.0171 0.169
FOXP1a NM_001244810.1 1 1 0 4 0 0.0286 0.244
GRIN2Ba NM_000834.3 3 3 0 2 0 0.00402 0.0703
GTPBP4 NM_012341.2 1 1 0 3 0 0.0479 0.311
LTN1 NM_015565.2 1 1 0 6 0 0.0102 0.12
MBD5a NM_018328.4 1 1 0 16 6 0.0343 0.273
MYT1L NM_015025.2 1 1 0 8 0 0.00365 0.0703
NAA15 NM_057175.3 2 2 0 5 3 0.0296 0.244
NCKAP1 NM_205842.1 2 2 0 7 0 0.00137 0.0564
NFIA NM_001134673.3 1 1 0 3 0 0.0479 0.311
NRXN1a NM_001135659.1 1 1 0 30 9 0.00427 0.0703
NTM NM_001144058.1 1 1 0 40 0 2.53 × 10−10 6.25 × 10−8
PCOLCE NM_002593.3 1 1 0 7 0 0.0061 0.0833
PHF2 NM_005392.3 1 1 0 4 0 0.0286 0.244
RAB2A NM_002865.2 1 1 0 3 0 0.0479 0.311
SCN1Aa NM_001165963.1 4 4 0 10 1 7.36 × 10−5 4.55 × 10−3
SCN2Aa NM_021007.2 6 5 0 10 0 7.34 × 10−7 6.04 × 10−5
SLC6A1 NM_003042.3 1 1 0 6 0 0.0102 0.12
SRM NM_003132.2 1 1 0 9 0 0.00218 0.0703
STXBP1a NM_003165.3 2 2 0 4 0 0.00641 0.0833
SUV420H1 NM_016028.4d 1 1 0 3 0 0.0479 0.31135
SYNGAP1a NM_006772.2 4 4 0 0 1 0.00252 0.0703
TBR1 NM_006593.2 2 2 0 7 1 0.00522 0.0806
UBN2 NM_173569.3 1 1 0 5 0 0.0171 0.169
WAC NM_016628.4 1 1 0 3 0 0.0479 0.31135
WDFY3 NM_014991.4 1 1 0 8 0 0.00365 0.0703
ZMYND11 NM_006624.5 1 1 0 8 0 0.00365 0.0703
LOF, loss of function.
aDisease gene in OMIM. bVariant 2; this is the major form of ankyrin in the adult brain. cVariant 2; this isoform and variants 3 and 4 are shorter than variant 1. dVariant 2; this isoform is shorter 
and has a distinct C terminus in comparison to isoform 1. ePlease see the Supplementary Note for discussion of the q values shown.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by Sanger sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identified by comparison 
with the MIP resequencing data for 2,193 unaffected siblings from 
the Simons Simplex Collection37 and ESP6500. We tested each gene 
for combined enrichment of loss-of-function variation across CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Supplementary Table 5) with a significant enrichment of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal truncating events, we applied a statistical model based 
on predicted protein lengths for genes with truncating or splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to the results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal threshold of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and four new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrome32 (P = 0.000418, q = 0.00155) in comparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striking phenotypic resem-
blance to microdeletion carriers, confirming this gene as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
1
Ath Ath Ath Rpt
1,597
SETSKI
p.Gly15Argfs*47
p.Arg143Valfs*64
p.Leu411Glyfs*6
p.Trp532* p.Arg625*
p.Arg626*
p.Ser1011*p.Lys592* p.Ile822Tyrfs*13
a
b
c
Filges et al.
LINC01478
RefSeq genes
SETBP1
MIR4319
SLC14A2
SLC14A1
SLC14A2
FLJ44087
Marseglia  et al.
18q12.3
Chr. 18
Scale
40,000,000 40,500,000
Chromosome bands localized by FISH mapping clones
41,000,000 41,500,000
hg181 Mb
SETBP1
6 years, 2 months
3 years, 8 months
34 years
17 years
19 years
SETBP1 p.Trp532*
SETBP1 p.Ser1011*
14 years
SETBP1 p.Ile822Tyrfs*13
SETBP1 p.Arg143Valfs*64
9896753
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9881150
9887952
Figure 1 Truncating SETBP1 mutations and 
associated phenotypes. (a) CNV data define a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eight truncating variants 
in SETBP1 and none in controls. Integration of 
published exome data identified one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous region;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarized in Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive facial features. See the Supplementary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by Sanger sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identified by comparison 
with the MIP resequencing data for 2,193 unaffected siblings from 
the Simons Simplex Collection37 and ESP6500. We tested each gene 
for combined enrichment of loss-of-function variation across CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Supplementary Table 5) with a significant enrichment of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal runcating events, we appli d a statistical model based 
on predicted protein lengths for genes with truncating or splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to the results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal threshold of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and four new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrome32 (P = 0.000418, q = 0.00155) in comparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striking phenotypic resem-
blance to microdeletion carriers, confirming this gene as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
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Figure 1 Truncating SETBP1 mutations and 
associated phen types. (a) CNV ata d fine a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eight truncating variants 
in SETBP1 and none in controls. Integration of 
published exome data identified one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous region;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarized in Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive facial features. See the Supplementary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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delay and 1,329 cases of ASD, totaling 4,716 cases. Putative loss-of-
function SNVs and indels were validated by San er sequencing and 
assessed in parental DNA, when available, to determine inheritance. 
Genes with significant enrichment were identifie  by comparison 
with the MIP resequencing data for 2,193 unaff cted siblings from 
th  Simons Simplex Collection37 and ESP6500. We tested each gen  
for combi ed e richment of loss-of-function a iation acro s CNV 
and SNV data (Online Methods) and identified 16 genes (Table 3 and 
Suppleme tary Table 5) with a significant enrichme t of disruptive 
mutations in cases. Additionally, to control for the differential effects 
of terminal truncating ev nts, w  applied a statistical model based 
on predicted protein l gths for genes with tr ati g o  splice-site 
events in ESP6500 (Supplementary Fig. 5), as this approach was com-
plementary to th  results from case-control 
comparison (Table 3).
Among the positive controls, our analy-
sis confirmed the pathogenicity of five genes 
using a nominal thresh ld of significance on 
the joint P values: ARID1B (five CNVs and 
nine truncating SNVs, one of which was 
confirmed to be de novo; P = 1.51 × 10−4, 
q = 6.54 × 10−4), GRIN2B (two CNVs—one focal CNV disrupting 
the distal end of GRIN2B—and f ur new truncating variants; P = 
0.00546, q = 0.0142) and MBD5 (P = 0.0429, q = 0.0744), as well 
as SCN1A (P = 0.0036, q = 0.0117), in comparison to the adjacent 
gene TTC21B (P = 1.00, q = 1.00). Integration of SNV and CNV 
data confirmed KANSL1 as the gene responsible for the 17q21.31 
deletion syndrom 32 (P = 0.000418, q = 0.00155) in omparison 
to the adjacent gene MAPT (P = 0.36, q = 0.455) (Table 3 and 
Supplementary Table 5). Clinical follow-up for one KANSL1 case 
with a severe frameshift demonstrated striki g phen typic resem-
blance to micr deletion carriers, confirming thi  ge e as the major 
contributor to the phenotype of 17q21.31 microdeletion (Koolen– 
de Vries) syndrome32,38.
Table 4 Brief phenotypic description of cases with SETBP1 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive
Hyperactive 
or ADHD
Social  
difficulties
Other  
behavioral  
difficulties
Speech 
delay
Motor  
delay
Facial  
dysmorphism
Seizures  
or EEG  
abnormalities
DNA03-00335 14 years M p.Ile822Tyrfs*13 De novo Normal IQ + + + +
DNA-008897 73 years M p.Leu411Glyfs*6 Profound ID + + + + +
Troina 1274 19 years M p.Trp532* De novo Severe ID + + + + −
Troina 1512 17 years M p.Ser1011* De novo Mild ID + (3y 8m) + + + + −
Troina 3097 34 years F p.Arg143Valfs*64 Severe ID + + + +
DNA11-21308Z 36 years F p.Arg625* Mild to  
moderate ID
+ + + + + +
DNA11-19324Z 9 years F p.Arg626* 2- to 2.5-year 
delay at  
9 years old
+ − + −
DNA08-08272 9 years M p.Gly15Argfs*47 Mild ID + + + + + +
Rauch et al. 13 years F p.Lys592* Mild ID + + + − +
9886269 5 years M Deletion De novo Global delay + + + + +
Marseglia et al. 15 years M Deletion De novo Mild ID + + + + + + +
Filges et al. pt. 1 7 years M Deletion De novo Moderate ID + + + +
Filges et al. pt. 2 4 years M Deletion De novo + + +
ID, intellectual disability;  EEG, electroencephalogram; M, male; F, female.
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Figure 1 Tru cating SETBP1 mutations and 
associated phenotypes. (a) CNV data define a focal 
CNV region around SETBP1. Combining a focal 
de novo deletion observed in our study (9886269) 
with CNVs from Filges et al.41 and Marseglia et al.42  
(red bars) highlights minimal common regions, 
including SETBP1 and LINC01478. (b) Targeted 
resequencing identified eigh  truncating variants 
i  SETBP1 and none in controls. Integration of 
published xome ata identifi d one additional 
case and no truncating events in controls.  
Ath, AT hook; SKI, SKI-homologous regi n;  
SET, SET-binding domain; Rpt, repeat. (c) Phenotypic 
assessment (summarize  i  Table 4) identified 
a recognizable phenotype, including IQ deficits 
ranging from mild to severe, impaired speech and 
distinctive faci l features. See th  Suppleme tary 
Note for additional photographs of affected 
individuals and clinical descriptions. We obtained 
informed consent to publish the photographs.
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An enrichment of loss-of-function mutations in cases was observed 
for ten additional genes (ADNP, DYRK1A, NRXN1, NRG3, SETBP1, 
ZMYND11, DNM3, CYFIP1, FOXP1 and SCN2A) (Table 4). In one 
case with a de novo DYRK1A splice-site mutation (see Troina1818 
in Supplementary Table 5), the affected individual presented with 
severe microcephaly, consistent with published autism-related 
de novo truncating mutations and CNVs from earlier studies36,39. 
Among the genes for which there was no enrichment in cases ver-
sus controls, two were notable: CHD1L and ACACA—candidates 
for the 1q21 deletion and 17q12 deletion syndromes, respectively40. 
In our resequencing study of CHD1L, for example, we identified 
14 likely truncating variants (Table 3) in comparison to 9 inde-
pendent truncating variants in controls, which indicates that rare 
truncating mutations of CHD1L are not uncommon (Table 3 and 
Supplementary Table 5). There was also no significant decrease in 
the predicted protein size in cases in comparison to controls (P = 0.94, 
log-rank test).
Phenotypic examination of cases with SETBP1 and ZMYND11 
truncations
Among the significant genes, we focused on SETBP1 and ZMYND11 
for further phenotypic characterization. We confirmed a focal de novo 
deletion and five cases with truncating mutations (three tested and 
confirmed to be de novo) in the SETBP1 gene (encoding SET-binding 
protein 1). Disruptive mutations were absent in controls, with 
the exception of a splice-site alteration predicted to lead to the loss 
of an in-frame exon encoding 18 amino acids. Notably, all truncat-
ing mutations in cases occurred in cohorts of intellectual disability, 
where we observed an enrichment of mutations (P = 0.0093, joint 
loss of function) and decreased predicted protein size (P = 0.011, 
log-rank test) (Fig. 1, Table 3 and Supplementary Tables 5 and 6). 
Integration of our variants from cases with 2 additional truncating 
variants found in a separate genetic screen for intellectual disability 
(n = 847) with the same MIPs, as well as published small deletions 
and de novo variants, highlighted a similar phenotype for the affected 
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Figure 2 Truncating ZMYND11 mutations and associated phenotypes. (a) CNV data refine a focal CNV deletion region (red bars) containing two genes 
(ZMYND11 and DIP2C). (b) Targeted resequencing identified five truncating variants and one single-amino-acid deletion predicted to behave as loss-
of-function variants by removing a critical binding residue in the MYND domain (Gln587). Analysis of control resequencing and exome data identified 
no additional truncating events in ZMYND11 but highlighted two truncating mutations in DIP2C. PHD, plant homeodomain; Bromo, bromodomain; 
PWWP, conserved ProTrpTrpPro motif; NLS, nuclear localization sequence; MYND, zinc finger MYND type (myeloid, Nervy and DEAF-1); DMAP, DNA 
methyltransferase–associated protein; CaiC, crotonobetaine/carnitine-CoA ligase; AMP, AMP-dependent synthetase/ligase. (c) Phenotypic assessment 
(summarized in Table 5) showed a consistent phenotype characterized by mild intellectual disability accompanied by speech and motor delays, as 
well as complex neuropsychiatric behavioral and characteristic facial features. See the Supplementary Note for additional photographs of the affected 
individuals and clinical descriptions. We obtained informed consent to publish the photographs.
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individuals12,41,42. The majority of cases demonstrated IQ and lan-
guage deficits (completely absent or substantially impaired speech in 
92% (12/13) of the cases). Cases positive for mutation in SETBP1 also 
frequently exhibited impairment of fine motor skills (n = 8), hyper-
activity and/or ADHD (attention deficit and hyperactivity disorder) 
(n = 7) and autistic features and/or poor social skills (n = 4). We also 
observed a dysmorphism typified by a long face (n = 10), characteris-
tic eyebrows and, less frequently, low-set ears (n = 4) and café-au-lait 
spots (n = 4) (Fig. 1, Table 4 and Supplementary Table 6).
The smallest region of overlap for the 10p15.3 microdeletion 
predicted two possible candidate genes43: ZMYND11 and DIP2C  
(Fig. 2). We resequenced both candidates and detected five truncating 
variants in ZMYND11 (two confirmed to be de novo and one inherited 
from an affected father) and none in DIP2C. In contrast, concur-
rent examination of controls identified truncating mutations only for 
DIP2C (Fig. 2, Table 3 and Supplementary Table 5). Integration of 
CNV and truncating SNV data strongly supports ZMYND11 (devel-
opmental delay P = 2.81 × 10−5, joint loss of function) as opposed to 
DIP2C (developmental delay P = 0.48, joint loss of function) as the 
critical gene. Comparing the phenotypes of affected individuals with 
truncating SNVs in ZMYND11 (Fig. 2, Table 5 and Supplementary 
Table 7) showed a striking resemblance to the 10p15.3 microdele-
tion cases described previously43 and highlighted a consistent set 
of behavioral features, mild intellectual disability and subtle facial 
features, including hypertelorism (n = 6), ptosis (n = 3) and a wide 
mouth (n = 4). The most consistent features seen in all subjects 
were speech and motor delays, which were observed in all affected 
individuals for whom information was available, including in cases 
with CNVs43. Interestingly, a psychiatric phenotype was apparent in 
three of five affected individuals, including aggression in three of 
four males. Three cases were accessible for parental DNA testing, by 
which we determined that two variants were de novo and one was 
paternally inherited. The paternal carrier of the variant encoding 
p.Met187Ilefs*19 also had developmental delay, including walking 
at 3–4 years of age and learning problems, in addition to aggression 
in childhood with mood swings. We also detected a de novo in-frame 
deletion (encoding p.Gln587del) in the MYND domain (Gln587), 
which represents a critical residue in corepressor binding (including 
NCoR)44–46. Examination of this individual identified similarities 
with published 10p15.3 microdeletion syndrome cases (Fig. 2 and 
Supplementary Table 7), including characteristic facial dysmor-
phisms, global developmental delay and speech delay. Taking this 
evidence together, we propose that ZMYND11 is the critical gene 
associated with the 10p15.3 microdeletion syndrome.
DISCUSSION
In this study, we leverage the large sample size of cases avail-
able from CNV clinical microarrays and the precision of next-
generation sequencing to identify specific genes associated with 
 neurodevelopmental disease. The expanded CNV morbidity map 
offers clinical usefulness as a resource to assess the pathogenic rel-
evance of rare events, as well as a research tool to prioritize genes 
discovered from exome sequencing studies that are currently too 
underpowered to achieve statistical significance5–14,36. It is important 
to note that the large sample size (nearly 50,000 cases and controls) 
has begun to highlight regions that map outside of recurrent CNVs 
mediated by segmental duplications. The sample size is thus sufficient 
to survey the background level of CNVs, identifying critical regions 
outside of regions with elevated mutation rates (Table 2). In addition, 
the sample size has allowed the identification of various recurrent 
duplications (Supplementary Tables 2 and 3) that are neither neces-
sary nor sufficient to cause disease but are more likely to act as genetic 
modifiers or risk factors similar to the 15q11.2 microdeletion47. It is 
possible that copy number polymorphisms occurring at a frequency of 
>1% might also contribute as weaker risk factors, but such events are 
typically smaller and have not been sufficiently assayed by microar-
rays. We identify, for example, the 16p13.11 microduplication among 
68 cases in comparison to 27 controls, giving a likelihood ratio of 1.7 
(95% CI = 1.13–2.56). Exploring these high-impact risk factors will 
be important in understanding the genetic architecture of ASD and 
developmental delay and its relationship to that for other neuropsy-
chiatric features.
Under the assumption that different classes of genetic mutation 
(microdeletions and truncating SNVs and indels) will expose the 
same genic haploinsufficiency, we developed a joint probability sta-
tistic to identify 38 specific genes (Table 3) with a higher prior of 
disease involvement. Although we have not explored it here, a similar 
approach might be useful in assessing microduplications and hyper-
morphic missense mutations. Although it is clear that not all CNVs 
are monogenic and will be amenable to this integrated strategy, for-
ward resequencing of 23 candidate regions (including 6 controls) 
identified 11 genes where there is an excess of deletions and truncat-
ing mutations in cases in comparison to controls (Table 3). Targeted 
resequencing, in particular, allows the discrimination of adjacent 
genes within an SRO (that is, SCN1A versus TTC21B, KANSL1 versus 
MAPT or ZMYND11 versus DIP2C). A comparison of the frequency 
of truncating mutations in cases and controls also reduces the likeli-
hood that specific genes highlighted by case reports of atypical CNVs 
are pathogenic (for example, ACACA and CHD1L)40.
Follow-up and phenotypic evaluation in cases provide the most 
compelling evidence that we have identified genes that likely under-
lie CNV haploinsufficiency. Studies of cases with microdeletion and 
translocation originally narrowed a 1-Mb deletion region on chro-
mosome 18q12.3 to a 372-kb critical region spanning three genes 
(SETBP1, SLC14A2 and MIR4319)41,42. We identified five truncat-
ing mutations (three of three tested and confirmed to be de novo) in 
SETBP1 among cases with moderate to severe intellectual disability. 
The phenotypic similarity among microdeletion cases and cases with 
Table 5 Brief phenotypic description of cases with ZMYND11 loss-of-function variants
Case
Age at  
examination Sex Alteration Inheritance Cognitive Speech delay
Social  
difficulties
Behavioral 
problems
Facial  
dysmorphism
Adelaide20124 4 and 9 years F p.Gln587del De novo Global DD + + +
Adelaide3553 22 years M p.Asn152Thrfs*26 Global DD + +
DNA-017151 17 years F p.Thr70Asnfs*12 De novo Normal IQ + + + +
DNA04-02424 41 years M p.Gln326* Mild ID + + + +
DNA05-04370 M p.Glu416Serfs*5 Severe ID + + +
DNA-013587 25 years M p.Met187Ilefs*19 Inherited Global DD + + + +
Father of DNA-013587 M p.Met187Ilefs*19 Carrier DD +
DD, developmental delay; ID, intellectual disability; M, male; F, female.
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Abstract
To identify previously reported disease mutations that are compatible with
extraordinary longevity, we screened the coding regions of the genomes of 44
Ashkenazi Jewish centenarians. Individual genome sequences were generated
with 309 coverage on the Illumina HiSeq 2000 and single-nucleotide variants
were called with the genome analysis toolkit (GATK). We identified 130 coding
variants that were annotated as “pathogenic” or “likely pathogenic” based on
the ClinVar database and that are infrequent in the general population. These
variants were previously reported to cause a wide range of degenerative, neo-
plastic, and cardiac diseases with autosomal dominant, autosomal recessive, and
X-linked inheritance. Several of these variants are located in genes that harbor
actionable incidental findings, according to the recommendations of the Ameri-
can College of Medical Genetics. In addition, we found risk variants for late-
onset neurodegenerative diseases, such as the APOE e4 allele that was even
present in a homozygous state in one centenarian who did not develop Alzhei-
mer’s disease. Our data demonstrate that the incidental finding of certain
reported disease variants in an individual genome may not preclude an extraor-
dinarily long life. When the observed variants are encountered in the context of
clinical sequencing, it is thus important to exercise caution in justifying clinical
decisions.
Introduction
Human genetic studies have linked many variants to
human diseases or nondisease phenotypes. How to handle
the incidental finding of a disease variant is a topic of
current discussion (Green et al. 2013a; Klitzman et al.
2013). Incidental findings often occur, when genome
sequencing data are screened for disease-causing variants
that are recorded in databases such as Online Mendelian
Inheritance in Man (OMIM) (Hamosh et al. 2005) or,
more recently, ClinVar (Landrum et al. 2014) and the
Genome Wide Association Studies (GWAS) catalog
ª 2014 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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MICROBIAL EVOLUTION
Global epistasis makes
adaptation predictable despite
sequence-level stochasticity
Sergey Kryazhimskiy,1,3*† Daniel P. Rice,1,3* Elizabeth R. Jerison,2,3 Michael M. Desai1,2,3†
Epistatic interactions between mutations can make evolutionary trajectories contingent
on the chance occurrence of initial mutations. We used experimental evolution in
Saccharomyces cerevisiae to quantify this contingency, finding differences in adaptability
among 64 closely related genotypes. Despite these differences, sequencing of 104 evolved
clones showed that initial genotype did not constrain future mutational trajectories.
Instead, reconstructed combinations of mutations revealed a pattern of diminishing-returns
epistasis: Beneficial mutations have consistently smaller effects in fitter backgrounds. Taken
together, these results show that beneficial mutations affecting a variety of biological
processes are globally coupled; they interact strongly, but only through their combined effect
on fitness. As a consequence, fitness evolution follows a predictable trajectory even though
sequence-level adaptation is stochastic.
E
pistatic interactions betweenmutations are
pervasive in microbial and viral systems
(1–6). In some cases, a single mutation can
open up previously unavailable opportuni-
ties for a population to colonize a new
metabolic niche (2) or survive in a previously
intolerable drug concentration (3). Such idio-
syncratic epistasis makes evolutionary trajecto-
ries dependent on the chance occurrence of
initial mutations that constrain or potentiate fu-
ture adaptation. This historical contingency can
render adaptation fundamentally unpredictable
(7). However, recent work has also provided evi-
dence for more systematic patterns of epistasis
(8–10), which can drive convergent phenotypic
evolution (11–13) or can lead to parallel adapta-
tion at the sequence level (14). These observa-
tions suggest that evolutionary outcomesmay be
statistically predictable ifmutations causing idio-
syncratic changes in adaptability are rare, and if
epistasis instead channels evolution into conver-
gent phenotypic or genotypic pathways.
To test how epistasis and historical contin-
gency affect the predictability of adaptation, we
conducted a hierarchical laboratory evolution
experiment in S. cerevisiae (fig. S1). In the first
phase of the experiment (“diversification”), we
created 432 independent lines from a single
haploid clone (the diversification ancestor, DivAnc)
isolated from an earlier long-term evolution ex-
periment (15).We evolved each line independently,
half at large and half at small population size, in
rich media in 96-well microplates for 240 genera-
tions (16).We then selected 64 clones (“founders”),
each from a different line, chosen to span a range
of fitness relative to the DivAnc (16) (table S1).
Founders differed from the DivAnc by 4.2 muta-
tions on average (16). In the second phase of the
experiment (“adaptation”), we founded 10 inde-
pendent replicate populations with each founder
and then allowed each of the resulting 640 lines
to adapt at large population size for 500 gen-
erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
ment of the extent to which genetic background
influences evolution.
The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
surement noise, inherent stochasticity of the evo-
lutionary process, and the identity of the founder
(16, 17). After 250 generations of adaptation, 49%
of the variance in fitness incrementwas attributed
to inherent evolutionary stochasticity, 17% to
measurement error, and 34% to founder iden-
tity; after 500 generations, 29% of the variance
in fitness increment was attributed to inherent
stochasticity, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of howrapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with higher initial fitness, driving the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further partitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-fitness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternatively, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptivemutations, as suggested by (8–10).
This epistasis could have two forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
of the fitness effect depends on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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and then allowed each of the resulting 640 lines
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erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
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The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
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stochasticity, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of ho rapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with higher i itial fitness, drivi g the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further partitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-f tness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternat vely, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptiv mutations, as suggested by (8–10).
This epistasis could have tw forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
f the fitness ffect dep nds on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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MICROBIAL EVOLUTION
Global epistasis makes
adaptation predictable despite
sequence-level stochasticity
Sergey Kryazhimskiy,1,3*† Daniel P. Rice,1,3* Elizabeth R. Jerison,2,3 Michael M. Desai1,2,3†
Epistatic interactions between mutations can make evolutionary trajectories contingent
on the chance occurrence of initial mutations. We used experimental evolution in
Saccharomyces c revi iae to quantify this contingency, finding differences in adaptability
among 64 closely related genotypes. Despite these differences, sequencing of 104 evolved
clones showed that i itial genotype did not constrain future mutational trajectories.
Instead, reconstructed combinations of mutations revealed a pattern of diminishing-returns
epistasis: Beneficial mutations have consistently smaller effects in fitter backgrounds. Taken
together, these results show that beneficial mutations affecting a variety of biological
processes are globally coupled; they interact strongly, but only through their combined effect
on fitness. As a consequenc , fitness evolution follows a predictable trajectory even though
sequence-level d ptation is stochastic.
E
pistatic interactions betweenmutations are
pervasive in microbial and viral systems
(1–6). In some cases, a single mutation can
open up previously unavailable opportuni-
ti for a pop lation to colonize a new
metabolic niche (2) or survive in previously
intolerable drug concentration (3). Such idio-
syncratic epistasis makes evolutionary trajecto-
ries dependent on the chance occurrence of
initial mutations that constrain or potentiate fu-
ture ada tation. This historical conti gency can
render adaptation fu dament lly unpredictable
(7). How v r, recent work has also provided evi-
dence for more systematic patterns of epistasis
(8–10), which can drive convergent phenotypic
evolution (11–13) or can lead to parallel adapta-
tion at the sequence level (14). These observa-
tions suggest that evolutionary outcomesmay be
statistically p edictable ifmutat ons causing idio-
syncratic changes in adaptability are rare, and if
epistasis instead channels evolution into conver-
gent phenotypic or genotypic pathways.
To test how epistasis and historical contin-
gency affect the predictability of adaptation, we
conducted a hierarchical laboratory evolution
experiment in S. cerevisiae (fig. S1). In the first
phase of the experiment (“diversification”), we
created 432 independent lines from a si gle
haploid clone (the diversification ancestor, DivAnc)
isolated from an earlier long-term evolution ex-
periment (15).We evo ved each line independently,
half at large an half at small po ul tion size, in
rich media in 96-well microplates for 240 g ra-
tions (16).We then selected 64 clones (“founders”),
each from a different line, chosen to span range
of fitness relative to the DivAnc (16) (table S1).
Founders differed from the DivAnc by 4.2 muta-
tions on average (16). In the second phase of the
experiment (“adaptation”), we founded 10 inde-
pendent replicate populations with each founder
and then allowed each of the resulting 640 lines
to adapt at large population size for 500 gen-
erations. This enabled us to compare variation
among lines descended from the same founder
(which reflects the inherent stochasticity of evo-
lution) to variation between lines descended from
different founders, thereby providing an assess-
ment of the extent to which genetic background
influences evolution.
The competitive fitness of each population
after 250 and 500 generations of the adaptation
phase increased on average by 3.3% and 6.6%,
respectively (Fig. 1A and table S2). However, not
all populations adapted at the same rate. Instead,
the initially large variation in fitness between
lines declined with time (Fig. 1A). We carried out
an analysis of variance (ANOVA) to partition ob-
served variance in fitness increase during the
adaptation phase into contributions from mea-
surement noise, inherent stochasticity of the evo-
lutionary process, and the identity of the founder
(16, 17). After 250 generations of adaptation, 49%
of the variance in fitness incrementwas attributed
to inherent evolutionary stochasticity, 17% to
measurem t error, and 34% to founder iden-
tity; after 500 generations, 29% of the variance
in fitness increment was attributed to inherent
toch st city, 21% tomeasurement error, and 50%
to founder identity (Fig. 1B and table S3). This
demonstrates that genetic background is a key
determinant of howrapidly apopulationwill adapt.
These differences in adaptability are not ran-
dom: Populations with lower initial fitness sys-
tematically adapt more rapidly than populations
with hig er initial fitness, driving the overall pat-
tern of convergent evolution in fitness (Fig. 1C).
We further artitioned the variation in fitness
increment attributed to founder identity and found
that after 250 generations of adaptation, 31% of
this variation was explained by the fitness of the
founder, whereas 3% was determined by its spe-
cific genotype; for 500 generations, these percent-
ages rose to 46% and 4%, respectively (Fig. 1B
and table S3). Thus, the differences in adaptabil-
ity between founders are almost entirely predicted
by their differences in fitness and are indepen-
dent of the specific mutations underlying this
fitness. The initial fitness of the founder therefore
predicts the average rate of adaptation in its de-
scendant lines (Fig. 1D). Although the effects of
specific genotype on adaptability are rare or weak,
they are significant (fig. S2 and tables S3 and S4).
A negative correlation between fitness and
adaptability has also been observed in prokary-
otes (11, 12), and it is consistent with the common
observation in evolution experiments that the
rate of increase in fitness slows down over time
(13, 18). Combined with this earlier work, our
results suggest a general “rule of declining adap-
tability” that holds for prokaryotes and eukary-
otes adapting to rich andminimalmedia. Further,
our observations support a stronger version of
this rule: Genotypes with lower fitness are more
adaptable than those with higher fitness, and dis-
tinct genotypes with identical fitness are equally
adaptable (up to the rare or weak exceptions
noted above). This is consistentwith the argument
recently presented in (13).
The rule of declining adaptability could arise
for two non-exclusive reasons. First, there could
be only a few ways to increase in fitness. In this
model, high-fitness founders have lower adapta-
bility because they have already acquired all or
most of the possible strong-effect beneficial mu-
tations: They are “running out” of beneficial mu-
tations. In contrast, low-fitness founders adapt
more quickly because they have not yet acquired
these mutations. More generally, some groups of
mutations may have redundant functional ef-
fects (e.g., those that knock out a given pathway).
In this case, the number of nonredundant ways
to increase fitness would be much smaller than
the number of distinct beneficial mutations. We
refer to this general form of the running-out-of-
mutations hypothesis as the “modular epistasis”
model [inspired by (14)]: Each beneficial muta-
tion improves a single module, mutations within
each module are redundant, and high-fitness
founders adapt more slowly because they have
fewer remaining modules to improve, especially
among those modules that confer the largest fit-
ness gains (16).
Alternatively, mutations arising in higher-fitness
backgrounds may be less beneficial than those
arising in lower-fitness backgrounds; that is,
diminishing-returns epistasis may be pervasive
among adaptivemutations, as suggested by (8–10).
This epistasis could have two forms. If epistasis is
idiosyncratic, mutations may often have widely
different effects in different genetic backgrounds
(possibly including sign epistasis, where the sign
of the fitness effect depends on genetic back-
ground), but the average effect of a beneficial
mutation is smaller in fitter backgrounds. On the
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Supplementary Figures
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Figure S1. Experimental design. We created many independent lines from a single clone
(DivAnc) which came from a previous evolution experiment in the same environment (15) and
evolved each of them for 240 generations (Diversification). We then selected a single “Founder”
clone from 64 of these lines (chosen to span a range of fitness) and evolved 10 independent
replicate populations descended from each Founder for 500 generations (Adaptation).
20
leads to a striking pattern of convergent evo-
lution, making fitness evolution relatively pre-
dictable. Despite this fitness-level convergence,
evolution remains highly stochastic at the geno-
type level, likely because many distinct muta-
tional paths can lead a population to any given
fitness.
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NONHUMAN GENETICS
Genomic basis for the convergent
evolution of electric organs
Jason R. Gallant,1,2* Lindsay L. Traeger,3,4* Jeremy D. Volkening,4,5 Howell Moffett,6,7
Po-Hao Chen,6,7,8 Carl D. Novina,6,7,8 George N. Phillips Jr.,9 Rene Anand,10
Gregg B. Wells,11 Matthew Pinch,12 Robert Güth,12 Graciela A. Unguez,12 James S. Albert,13
Harold H. Zakon,2,14,15†Manoj P. Samanta,16†Michael R. Sussman4,5†
Little is known about the genetic basis of convergent traits that originate repeatedly over
broad taxonomic scales. The myogenic electric organ has evolved six times in fishes to
produce electric fields used in communication, navigation, predation, or defense. We have
examined the genomic basis of the convergent anatomical and physiological origins of
these organs by assembling the genome of the electric eel (Electrophorus electricus)
and sequencing electric organ and skeletal muscle transcriptomes from three lineages
that have independently evolved electric organs. Our results indicate that, despite millions
of years of evolution and large differences in the morphology of electric organ cells,
independent lineages have leveraged similar transcription factors and developmental and
cellular pathways in the evolution of electric organs.
E
lectric fishes use electric organs (EOs) to
produce electricity for the purposes of com-
munication; navigation; and, in extreme cases,
predation and defense (1). EOs are a dis-
tinct vertebrate trait that has evolved at
least six times independently (Fig. 1A). The tax-
onomic diversity of fishes that generate elec-
tricity is so profound that Darwin specifically
cited them as an important example of con-
vergent evolution (2). EOs benefit as a model for
understanding general principles of the evolu-
tion of complex traits, as fish have evolved other
specialized noncontractile muscle-derived or-
gans (3). Furthermore, EOs provide a basis to
assess whether similar mechanisms underlie
the evolution of other specialized noncontrac-
tile muscle derivatives, such as the cardiac con-
duction system (4).
Electric organs are composed of cells called
electrocytes (Fig. 1B). All electrocytes have an
innervated surface enriched in cation-specific ion
channels and, on the opposite surface, an in-
vaginated plasma membrane enriched in sodium
pumps, and, in some species, ion channels as
well. The functional asymmetry of these cells,
and their “in-series” arrangement within each
organ, allows for the summation of voltages, much
like batteries stacked in series in a flashlight.
Although EOs originate developmentally from
myogenic precursors, they are notably larger than
muscle fibers (5). Further, they either lack the
contractile machinery clearly evident in electron
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Fig. 3. Diminishing-returns epistasis among spe-
cific mutations. The fitness effect of knocking
out genes gat2, whi2, and sfl1 declines with the
fitness of the background strain. The ho knockout
is a negative control. Error bars are SEM over bio-
logical replicates.
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•  “Yet	  despite	  their	  lack	  of	  apparent	  func)onal	  
rela)onship,	  these	  muta)ons	  are	  globally	  
coupled	  by	  diminishing-­‐returns	  epistasis;	  their	  
eﬀects	  are	  strongly	  mediated	  by	  background	  
ﬁtness	  but	  are	  otherwise	  essen)ally	  
independent	  of	  the	  speciﬁc	  iden)ty	  of	  
muta)ons	  present	  in	  the	  background.	  The	  
biological	  basis	  of	  this	  global	  coupling	  remains	  
unknown”.	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A B S T R A C T
Purpose
Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the
performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a
representative clinical sample.
Methods
Patients referred for clinical BRCA1/2 testing from 2002 to 2012 were invited to donate a research
blood sample. Samples were frozen at !80° C, and DNA was extracted from them after 1 to 10
years. The entire coding region, exon-intron boundaries, and all known pathogenic variants in other
regions were sequenced for 42 genes that had cancer risk associations. Potentially actionable
results were disclosed to participants.
Results
In total, 198 women participated in the study: 174 had breast cancer and 57 carried germline
BRCA1/2mutations. BRCA1/2 analysis was fully concordant with prior testing. Sixteen pathogenic
variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4
among 141 women without BRCA1/2 mutations. Fourteen participants carried 15 pathogenic
variants, warranting a possible change in care; they were invited for targeted screening
recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy.
Participants carried an average of 2.1 variants of uncertain significance among 42 genes.
Conclusion
Among women testing negative for BRCA1/2 mutations, multiple-gene sequencing identified 16
potentially pathogenic mutations in other genes (11.4%; 95% CI, 7.0% to 17.7%), of which 15
(10.6%; 95% CI, 6.5% to 16.9%) prompted consideration of a change in care, enabling early
detection of a precancerous colon polyp. Additional studies are required to quantify the penetrance
of identified mutations and determine clinical utility. However, these results suggest that
multiple-gene sequencing may benefit appropriately selected patients.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Clinical genetic testing for cancer-risk assessment
has become widespread over the last two decades,
with evidence-based testing guidelines for heredi-
tary breast and ovarian cancer (BRCA1 andBRCA2;
BRCA1/2), Lynch syndrome (MLH1, MSH2,
MSH6, PMS2, and EPCAM), familial adenomatous
polyposis (APC), hereditary diffuse gastric cancer
(CDH1), Li-Fraumeni syndrome (TP53), Cowden’s
syndrome (PTEN), and a few other conditions.1-4
Cancer genetic counseling and risk-reducing in-
terventions have accordingly been developed for
high penetrance, autosomal dominant conditions.
Most of these interventions, especially prophylactic
surgery, are excessive for carriers of mutations that
have uncertain pathogenicity.5-7 Recently, next-
generation technology has enabled massively paral-
lel sequencing at low cost, and panels of multiple
cancer-associated genes are newly available for clin-
ical use.8,9
Despite these advances in technology, a critical
knowledgedeficit remains about the clinical valueof
multiple-gene panels for cancer susceptibility. Ma-
jor questions include howmany andwhich genes to
sequence, whether results are sufficiently under-
stood to guide intervention, and how best to coun-
sel patients about variants of low or moderate
penetrance.8,10-12 We designed a customized germ-
line sequencing panel of 42 cancer-associated genes
and evaluated its information yield among women
referred for clinical evaluation of hereditary breast
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“There	  are	  ~12	  billion	  nucleo)des	  in	  every	  cell	  of	  the	  human	  body,	  and	  there	  are	  
~25-­‐100	  trillion	  cells	  in	  each	  human	  body.	  Given	  soma)c	  mosaicism,	  epigene)c	  
changes	  and	  environmental	  diﬀerences,	  no	  two	  human	  beings	  are	  the	  same,	  
par)cularly	  as	  there	  are	  only	  ~7	  billion	  people	  on	  the	  planet”.	  	  


In	  the	  year	  2014….	  
This:	  
Is	  orders	  of	  magnitudes	  easier	  than	  
this:	  
Clinical	  Validity	  with	  Worldwide	  
Human	  Gene)c	  Varia)on	  “database”?	  
Pa;entsLikeMe	  
100,000	  Bri;sh	  Genomes	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked	  for	  thousands	  of	  
volunteer	  families.	  
Pa;entsLikeMe	  
Lost	  in	  Transla)on	  
•  We	  need	  to	  focus	  on	  the	  extremes,	  i.e.	  severe	  illness,	  
not	  just	  the	  “average”	  person,	  i.e.	  a	  new	  focus	  on	  rare	  
variant	  diseases	  uncovers	  fundamentally	  important	  
biological	  processes.	  
•  Many	  exci)ng	  gene)c	  discoveries	  are	  being	  made	  and	  
published.	  
•  There	  is	  much	  fanfare	  and	  media	  coverage.	  
•  But,	  then	  the	  gene)c	  researchers	  move	  on	  to	  the	  next	  
disease,	  expec)ng	  someone	  else	  will	  engage	  with	  the	  
families	  and	  perform	  counseling,	  educa)on	  and	  carrier	  
screening.	  
•  This	  does	  not	  happen	  mostly	  (certainly	  not	  always).	  	  
•  Only	  0.5%	  of	  the	  38	  MILLION	  published	  papers	  are	  cited	  
more	  than	  200	  )mes,	  and	  HALF	  are	  never	  cited	  (from	  
Topol,	  Crea)ve	  Destruc)on	  of	  Medicine,	  2012).	  
Systemic	  Barriers	  
•  Some)mes	  just	  simple	  lack	  of	  communica)on	  
between	  researchers	  and	  the	  physicians	  and	  
gene)c	  counselors.	  
•  We	  only	  have	  1500	  medical	  gene)cists	  and	  2000	  
cer)ﬁed	  gene)c	  counselors	  for	  310	  million	  
people	  in	  America!	  	  
•  Insurance	  will	  ohen	  deny	  coverage	  of	  gene)c	  
tes)ng,	  par)cularly	  for	  novel	  muta)ons,	  so	  
gene)c	  tes)ng	  is	  much	  under-­‐u)lized	  rela)ve	  to	  
procedure-­‐based	  medicine.	  
Systemic	  Barriers	  cont….	  
•  Physicians	  and	  health	  care	  system	  woefully	  
uneducated	  regarding	  gene)cs.	  
•  Current	  sequencing	  (exomes	  and	  whole	  
genomes)	  being	  sequenced	  in	  random	  
laboratories	  with	  no	  clinical	  standards	  in	  place	  
(although	  people	  trying	  to	  change	  this).	  
The	  End	  of	  Main	  Talk:	  
VigneXes	  to	  follow,	  if	  )me	  allows.	  
VigneXe	  #1:	  Discovering	  a	  new	  
syndrome	  and	  its	  gene)c	  basis.	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
VigneXe	  #2:	  New	  Syndrome	  with	  
Mental	  Retarda)on,	  “Au)sm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  Retarda)on	  
“au)sm”	  
“ADHD”	  
Hearing	  diﬃcul)es	  
UFBR	  Family	  3	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene)c	  tests	  nega)ve,	  including	  
nega)ve	  for	  Fragile	  X	  and	  MANY	  candidate	  
genes.	  
Sequenced	  whole	  genomes	  of	  Mother,	  Father	  
and	  Two	  Boys,	  using	  Complete	  Genomics	  
•  Sequenced	  “whole”	  genomes	  to	  obtain	  noncoding	  and	  
other	  non-­‐exonic	  regions.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  ~6	  million	  variants	  total	  in	  the	  4	  people	  diﬀerent	  from	  
Hg19	  reference	  genome.	  
•  No	  homozygous	  autosomal	  recessive	  muta)ons	  found.	  
•  No	  Nonsense/Frameshih	  muta)ons	  in	  both	  boys.	  
•  2	  muta)ons	  present	  in	  mother	  and	  two	  boys,	  on	  X-­‐
chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  not	  in	  
1000Genomes	  April	  2012	  release,	  and	  not	  in	  NHLBI	  
6500	  Exomes	  
	  


CADD$full
Disease&model Location Reference&allele Alternative&allele CADD&score Annotation&software Function
Autosomal$recessive chr1:210851705 TT T 27.5 ANNOVAR,$GEMINI,$SVS UTR3
Autosomal$recessive chr1:224772440 AATAATTTG TA 22.1 GEMINI intergenic
Autosomal$recessive chr2:60537356 TTTTATTT ATTATTA 22.3 GEMINI intergenic
Autosomal$recessive chr8:109098066 AT A 24.6 GEMINI intergenic
Autosomal$recessive chr15:66786022 ACAAA A 23.6 GEMINI intronic:SNAPC5
Autosomal$recessive chr16:49061346 TA T 25.3 ANNOVAR,$GEMINI intergenic
Autosomal$recessive chr16:49612367 GAC G 20.5 GEMINI,$SVS intronic:ZNF423
XQlinked chrX:70621541 T C 22.9 ANNOVAR,$GEMINI,$SVS TAF1:NM_138923:I1316T
Coding$full
Disease&model Location Reference&allele Alternative&allele Gene&name Annotation&software Function
DeQnovo chr1:53925373 G GCCGCCC DMRTB1 GEMINI,$SVS nonframeshift
Autosomal$recessive chr10:135438929 T G FRG2B ANNOVAR,$GEMINI,$SVS NM_001080998:I171L
Autosomal$recessive chr10:135438951 GGCCC AGCCT FRG2B GEMINI,$SVS nonframeshift
Autosomal$recessive chr10:135438967 C T FRG2B GEMINI,$SVS NM_001080998:R158Q
Autosomal$recessive chr15:85438314 C CTTG SLC28A1 GEMINI nonframeshift
XQlinked chrX:34961492 T C FAM47B GEMINI NM_152631:Y182H
XQlinked chrX:70621541 T C TAF1 ANNOVAR,$GEMINI,$SVS NM_138923:I1316T
X:70621541-­‐SNV	  	  Nonsyn	  SNV	  	  TAF1	  	  	  c.4010T>C	  	  	  p.Ile1337Thr	  
	  
2	  muta)ons	  present	  in	  mother	  and	  two	  boys,	  on	  
X-­‐chromosome,	  not	  in	  father,	  not	  in	  dbSNP135,	  
not	  in	  1000Genomes	  April	  2012	  release,	  and	  not	  
in	  NHLBI	  6500	  Exomes	  
	  
•  Nonsyn	  SNV	  	  	  ZNF41	  	  	  	  c.1191C>A	  	  p.Asp397Glu	  	  
	  	  
•  Nonsyn	  SNV	  	  	  TAF1	  	  	  	  	  	  	  c.4010T>C	  	  p.Ile1337Thr	  	  
	  
TAF1	  RNA	  polymerase	  II,	  TATA	  box	  binding	  protein	  
(TBP)-­‐associated	  factor,	  250kDa	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
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ated. Accounting for 2%–2.5% of the established X-
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip)on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip)onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac)on	  module	  
which	  represses	  transcrip)on	  through	  recrui)ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma)n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma)n	  
modula)ng	  proteins,	  leading	  to	  transcrip)onal	  repression	  
through	  heterochroma)n	  forma)on.	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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
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abstract
BACKGROUND: The combination of microcephaly, pyramidal signs, abnormal corpus callosum, and intellectual
disability presents a diagnostic challenge. We describe an autosomal recessive disorder characterized by micro-
cephaly, pyramidal signs, thin corpus callosum, and intellectual disability. METHODS: We previously mapped the
locus for this disorder to 8q23.2-q24.12; the candidate region included 22 genes. We performed Sanger sequencing
of 10 candidate genes; to ensure other genes in the candidate region do not harbor mutations, we sequenced the
exome of one affected individual. RESULTS: We identiﬁed two homozygous missense changes, p.Thr186Arg and
p.Pro416His in TAF2, which encodes a multisubunit cofactor for TFIID-dependent RNA polymerase IIemediated
transcription, in all affected individuals. CONCLUSIONS: We propose that the disorder is caused by the more
conserved mutation p.Thr186Arg, with the second sequence change identiﬁed, p.Pro416His, possibly further
negatively affecting the function of the protein. However, it is unclear which of the two changes, or maybe both,
represents the causative mutation. A single missense mutation in TAF2 in a family with microcephaly and intel-
lectual disability was described in a large-scale study reporting on the identiﬁcation of 50 novel genes. We suggest
that a mutation in TAF2 can cause this syndrome.
Keywords: Microcephaly syndrome, TAF2, corpus callosum, pyramidal, autosomal recessive
Pediatr Neurol 2013; 49: 411-416
! 2013 Elsevier Inc. All rights reserved.
Introduction
The combination of microcephaly, pyramidal signs,
abnormal corpus callosum, and intellectual disability in
pediatric patients presents a diagnostic challenge. We
recently described a previously unreported syndrome
characterized by a progressive postnatal decline in head
circumference to between !2 and !5.5 standard deviations
within a few months of birth accompanied by pyramidal
signs (spasticity, brisk tendon reﬂexes, and extensor plantar
reﬂex), thin corpus callosum, and intellectual disability.1
The differential diagnosis of this combination of clinical
and radiological features includes several disorders.
Although autosomal recessive primary microcephaly can
present with a normal head circumference at birth, devel-
opmental impairment is usually milder and brain magnetic
resonance imaging typically shows a simpliﬁed gyral
pattern.2 The disease caused by mutations in TRAPPC9 is a
form of autosomal recessive nonsyndromic intellectual
disability associated with variable postnatal microcephaly.3
Spasticity with a thin corpus callosum may be part of
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Structural and functi n l insight into TAF1–TAF7,
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Transcription factor II D (TFIID) is a multiprotein complex that
nucleates formation of the basal transcription machinery. TATA
binding protein-associated factors 1 and 7 (TAF1 and TAF7), two
subunits of TFIID, are integral to the regulation of eukaryotic tran-
scription initiation and play key roles in preinitiation complex (PIC)
assembly. Current models suggest that TAF7 acts as a dissociable
inhibitor of TAF1 histone acetyltransferase activity and that this
event ensures appropriate assembly of the RNA polymerase II-
mediated PIC before transcriptional initiation. Here, we report the
3D structure of a complex of yeast TAF1 with TAF7 at 2.9 Å reso-
lution. The structure displays novel architecture and is character-
ized by a large predominantly hydrophobic heterodimer interface
and extensive c folding of TAF subunits. Ther are no obvious
similarities betwe n TAF1 and known histone acetyltrans-
ferases. Instead, the surface of the TAF1–TAF7 complex contains
two prominent conserved surface pockets, one of which binds
selectively to an inhibitory trimethylated histone H3 mark on
Lys2 in a manner that is also r gulated by phosphorylation at
the neighbo ing H3 serine. Our findings could point toward novel
roles for the TAF1–TAF7 complex in regulation of PIC assembly via
reading epigenetic histone marks.
initiation complex | protein structure | protein–protein interaction |
X-ray crystallography
The general transcription factor II D (TFIID) plays a centralrole in recognition of the core promoter element and medi-
ates accurate transcription initiation by RNA Polymerase (Pol)
II for a large class of genes. TFIID nucleates the formation of
the preinitiation complex (PIC) at the transcriptional start site by
recruiting other general transcription factors (TFII-A, -B, -E, -F,
and -H), along with RNA Pol II. TFIID is assembled in a step-
wise manner, with a symmetric TFIID core complex recruited
first, followed by further recruitment of additional TATA binding
protein (TBP)-associated factors (TAFs) to form the complete
asymmetric holo–TFIID complex (1). This megadalton-sized
multiprotein assembly, comprised of TBP and 13 evolutionary
conserved TAFs (2), is organized into a trilobed structure (3)
and undergoes striking rearrangements upon binding to TFIIA
and DNA (4). TAF subunits serve multiple functions within the
TFIID holocomplex. In addition to TBP, TAF1, TAF2, TAF6,
and TAF9 are also involved in recognition of DNA initiator and
promoter elements. Moreover, TFIID can behave as an epige-
netic effector, capable of recognizing posttranslational histone
modifications associated with activated transcription. Eukaryotic
TAF1 contains a double bromodomain that recognizes acety-
lated histones, and TAF3 contains a plant homeo domain (PHD)
that binds to histone H3 methylated at lysine 4 (5, 6). In addition
to roles in basal transcription, TFIID is also associated with dis-
eases. Overexpression of TAF1, which acts as a specific coac-
tivator of androgen receptor, is related to the progression of
human prostate cancer (7). Additionally, alterations of TAF gene
copy numbers and mutations are reported in high-grade serous
ovarian cancer (8).
TAF1, the largest subunit of TFIID, plays a particularly im-
portant role in TFIID complex activity (9, 10). Unlike other
TAFs, it spans two lobes (from C through A) within the trilobed
structure of TFIID, as indicated by EM and immunomapping
stu ies, with the TAF1 C terminus located in the A lobe (3, 11).
TAF1 is c mprised of multiple separabl domains that variously
harbor HAT and kinas activities, TAND domain th t binds
TBP, DNA bi ding functions, and the aforementioned double
bromodo ain that contacts acetylated histone tails (5, 9, 10).
Yeast TAF1 (yTAF1) ret ins the HAT, TAND, and C-terminal
DNA recognition domains (12), and ∼90% of yeast gene ex-
pression is TAF1 dependent (13). Current reports suggest that
TAF7 exerts transcriptional ch ckpoint control activit by be-
having as a dissociable inhibitor f TAF1 HAT activity; this
event serves to ensure correct PIC assembly for effective Pol
II-mediated transcription initiation and is essential for progres-
sion through the cell cycle (14, 15).
Although crystal structures of small fragments of the TAF1
double bromodomain (5) and TAND domain bound to TBP
(16) are available, the structure of the large putative TAF1
HAT domain and the basis of its molecular interaction with
TAF7 remain unknown. To gain insight into TAF1–TAF7
Significance
Transcription factor II D (TFIID) is a multiprotein complex that is
essential for gene transcription. Together, TATA binding pro-
tein-associated factor 1 (TAF1), the biggest TFIID subunit, and
TAF7 form an important control point for transcriptional initi-
ation. Although current models suggest that TAF7 binds TAF1
to block its intrinsic histone acetyltransferase (HAT) activity,
almost nothing is known about the molecular basis of TAF1–
TAF7 (TAF1/7) interaction and TAF1 activity. Here, we report
the atomic structure of the yeast TAF1/7 heterodimer and
probe its function using biochemical techniques. Our structure
suggests that yeast TAF1 is not a HAT and instead reveals that
TAF1/7 displays the unexpected capacity to bind a specific re-
pressive histone mark. This raises the possibility that TFIID
binds repressive chromatin marks to control gene expression.
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